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SUMMARY 
The aim of this study was to compare the effects on MAC, cardiopulmonary 
function and recovery quality of S(+)-ketamine or medetomidine CRIs in 
isoflurane anaesthetised horses after induction of anaesthesia with either S(+)- 
or racemic ketamine.  
Fifty horses were randomly assigned to two groups, S-ket and Med, and the 
observer was blinded. Horses were sedated with medetomidine. Anaesthesia 
was induced with midazolam and 1.1 mg kg-1 S(+)-ketamine (S-ket) or 2.2 mg 
kg-1 racemic ketamine (Med) and maintained with isoflurane in oxygen and 0.5 
mg kg-1 h-1 S(+)-ketamine or 3.5 µg kg-1 h-1 medetomidine and thiopental as 
rescue drug. Cardiopulmonary function was monitored and recovery timed and 
scored. 
No differences between the groups concerning age, weight and duration of 
anaesthesia were found. Both groups required the same concentrations of 
isoflurane to maintain anaesthesia, but the need for thiopental was higher in S-
ket group. No clinically relevant differences in cardiopulmonary function were 
found between groups. Only cardiac index was higher in S-ket group. 
Horses in S-ket group regained sternal and standing position faster. Recovery 
scores were better in Med group. In S-ket group, recovery quality decreased 
with CRI duration. 
It was concluded that S(+)-ketamine CRI and medetomidine CRI during 
isoflurane anaesthesia resulted in acceptable cardiopulmonary function in 
horses. Horses recovered faster with S(+)-ketamine, but quality of recovery was 
better with medetomidine. 
 
Key words: Horses, isoflurane anaesthesia, CRI, S(+)-ketamine, medetomidine  
 
 
 
 
 
 
 
 
 
 
 
3 
 
ZUSAMMENFASSUNG 
Ziel dieser Studie war, den Einfluss auf die MAC, die kardiopulmonäre Funktion 
und die Aufwachqualität einer CRI von S(+)-Ketamin oder Medetomidin 
während einer Isoflurananästhesie bei Pferden nach Einleitung mit S(+)-
Ketamin oder Ketaminrazemat zu vergleichen.   
Für diese Doppelblindstudie wurden 50 Pferde zufällig in 2 Gruppen eingeteilt, 
S-ket und Med. Alle Pferde wurden mit Medetomidin sediert. Die Anästhesie 
wurde mit Midazolam und 1.1 mg kg-1 S(+)-Ketamin (S-ket) oder 2.2 mg kg-1 
Ketaminrazemat (Med) eingeleitet und mit Isofluran in Sauerstoff und 0.5 mg 
kg-1 h-1 S(+)-Ketamin oder 3.5 µg kg-1 h-1 Medetomidin sowie bei Bedarf 
Thiopental aufrecht erhalten. Die kardiopulmonären Parameter wurden 
überwacht, die Aufwachphase bewertet. 
Alter, Gewicht und Anästhesiedauer waren in beiden Gruppen gleich. Beide 
Gruppen benötigten die gleiche Isoflurankonzentration um die Anästhesie 
aufrechtzuerhalten, jedoch war der Thiopentalbedarf in der S-ket Gruppe höher. 
Es gab keinen klinisch relevanten Unterschied in der kardiopulmonären 
Funktion. Einzig der Herzindex war in der S-ket Gruppe höher. 
Pferde der S-Ket Gruppe nahmen die sternale und stehende Position schneller 
ein. Die Aufwachscores waren in der Med Gruppe besser. In der S-ket Gruppe 
verschlechterte sich die Aufwachqualität mit der Infusionsdauer. 
Pferde der S-Ket und Med Gruppe zeigten eine akzeptable kardiopulmonäre 
Funktion. Mit S(+)-Ketamin standen die Pferde schneller auf, aber die 
Aufwachqualität war besser mit Medetomdin.  
 
Schlüsselwörter: Pferde, Isoflurananästhesie, CRI, S(+)-Ketamin, Medetomidin 
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1. INTRODUCTION 
In horses, surgical procedures of longer duration are usually performed under 
inhalation anaesthesia. However, volatile anaesthetic agents cause a dose-
dependent cardiovascular depression, a major cause of death in equine 
anaesthesia (Johnston et al. 2002). Respiratory depression is frequent in 
anaesthetised horses. Recovery is one of the most critical phases of equine 
anaesthesia and is often associated with bone fractures, joint dislocations, 
haemorrhages, head traumas and dehiscence of surgical wounds (Clark-Price 
et al. 2008).  
The technique of balanced anaesthesia is based on the concept that the co-
administration of a mixture of small amounts of several drugs shall produce an 
ideal anaesthetic state (Muir & Yamashita 2000). Thus, the advantages, but not 
the disadvantages, of the individual components of the mixture are summated. 
Medetomidine is an alpha2-adrenoreceptor agonist that has been used in 
horses as constant rate infusion (CRI) together with isoflurane and its use is 
well established in equine anaesthesia. In clinical patients the use of a CRI of 
medetomidine in combination with isoflurane compared to isoflurane 
anaesthesia alone, resulted in significantly reduced isoflurane requirements 
(Neges et al. 2003). Further, adjustment of anaesthetic depth was easier with 
medetomidine and less additional drugs had to be administered in order to 
deepen anaesthesia. A comparison of medetomidine infusions during isoflurane 
anaesthesia with lidocaine infusions, a commonly used drug for balanced 
anaesthesia in horses, showed much better recoveries following medetomidine 
CRI (Ringer et al. 2007). At the Equine Department of the Vetsuisse Faculty of 
Zurich, anaesthesia is usually induced with racemic ketamine, and maintained 
with isoflurane and a constant rate infusion of medetomidine.  
Commercially available ketamine for veterinary use is mostly a racemic mixture 
of two optical isomers: S(+)- and R(-)-ketamine. Racemic ketamine is 
considered to be safe and effective for most equine anaesthetic procedures, 
either during field surgery or hospital conditions. Addition of racemic ketamine 
to volatile anaesthetics (i.e. halothane, isoflurane) as part of balanced 
anaesthesia in horses reduced MAC and resulted in better cardiopulmonary 
function (Bettschart-Wolfensberger & Larenza 2007). However, racemic 
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ketamine can induce emergence reactions during the post-anaesthetic recovery 
period, characterized by muscular tremor, rigidity and ataxia that can turn into a 
fatal event in horses (Muir & Sams 1992, Larenza et al. 2009). Therefore the 
use of racemic ketamine infusion is limited to procedures lasting less than 2 
hours (Larenza et al. 2009). In the last years, the single S(+)-isomer has 
become available for use in cats. A preliminary study in ponies demonstrated 
that S(+)-ketamine provided an identical depth of immobility after a single 
injection of half dose of racemic ketamine with a more rapid recovery (Larenza 
et al. 2007), probably caused by faster S(+)-ketamine elimination. In horses, a 
significantly better anaesthesia recovery was also observed after a constant 
rate infusion of S(+)-ketamine compared with racemic ketamine infusions 
(Larenza et al. 2009).  
 
The aim of the present study was to compare the effects of a S(+)-ketamine 
CRI with a medetomidine CRI during isoflurane anaesthesia in horses induced 
with either S(+)-ketamine or racemic ketamine on MAC and cardiopulmonary 
function and the resulting recovery . 
 
2. BACKGROUND  
2.1 Isomerism 
2.1.1 Introduction 
In chemistry, isomers are compounds with the same molecular formula, but 
different structures (Kemnitz & Simon 2005). Isomerism is the occurrence of 
such compounds. The term "isomer" is derived from greek words "isos" which 
means "equal", and "méros" which means "part" (Haubrich 2003). Even if 
isomers have the same number of atoms and the same molecular weight, they 
differ in their properties. 
Friedrich Wöhler and Justus von Liebig were both involved in the discovery of 
isomerism. They found that cyanic acid had the same composition as fulmaric 
acid, but that its properties were different. During the years 1849 - 1853, Louis 
Pasteur investigated on tartaric and racemic acids. He separated racemic 
tartaric acid into two optically active components by crystallization. These acids 
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had an identical chemical composition and structure, but different properties 
(Wheland & Mills 1964). 
In 1992, the Food and Drug Administration claimed that separation of isomers 
had not received adequate attention in drug development and that, despite 
technical difficulties and high costs, focussing on this new issue could open 
new therapeutic horizons (Kohrs & Durieux 1998). 
 
2.1.2 Classification 
There are two main forms of isomerism: structural (or constitutional) isomerism 
and stereoisomerism. 
 
2.1.2.1 Structural isomerism 
Two or more substances are said to be structural isomers of each other if they 
have the same chemical composition, but different structures (Wheland 1964). 
That means that their atoms are bonded together in different orders. These 
differences give the molecules different chemical and physical properties. There 
are different categories of structural isomerism: chain isomerism (or skeletal 
isomerism), position isomerism, functional group isomerism (Wheland 1964) 
and tautomerism.  
 
A. Chain isomerism 
Chain or skeletal isomers occur because of different possibilities of a branching 
component of the skeleton.  
In the example below, butane is constituted of a straight chain, whereas its 
isomer isobutane has a branched chain (Figure 1). Both molecules have the 
same molecular formula C4H10, but different constitutions. 
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Figure 1- Chain isomerism (http://medical-dictionary.thefreedictionary.com) 
 
B. Position isomerism 
In position isomerism, the basic carbon skeleton remains unchanged, but 
important functional groups change their position in the chain. For example, 1-
propanol, CH3CH2CH2OH, and 2-propanol, CH3CH(OH)CH3, are position 
isomers, because their functional group (the OH-group) has a different location 
in the carbon chain. 
The functional group can also be located on different parts of a benzene ring 
(Figure 2). There are three isomers of toluidine which all have the same 
molecular formula C7H9N. The difference between these three isomers is the 
position where the methyl group (-CH3) is bonded to the ring relative to the 
amino functional group (-NH2). In o-toluidine, the methyl group is located next to 
the amino group, in m-toluidine it is located next-but one to the amino group 
and in p-toluidine it is located opposite to the amino group.  
 
Figure 2- Position isomers of toluidine (Wikipedia) 
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C. Functional group isomerism 
Functional isomerism occurs when substances have the same molecular 
formula, but different functional groups. 
 
 
       Ethanol   Methoxymethane 
Figure 3- Functional group isomerism (www.creative-chemistry.org.uk) 
Ethanol (CH3CH2-OH), an alcohol, has the functional hydroxyl group (-OH), 
methoxymethane (CH3-O-CH3) the functional R-O-R’ group. Both substances 
have the same molecular formula C2H6O (Figure 3).  
 
D. Tautomerism 
Tautomers are structural isomers that easily convert between two isomeric 
forms by a chemical reaction called tautomerization. They therefore exist in 
equilibrium. This reaction commonly results in the migration of a hydrogen atom 
and a switch of a single bond to an adjacent double bond. A common example 
is the keto-enol tautomerism (Figure 4). The hydrogen atom bonded to the 
carbon atom in the carbonyl (keto) group (-CH-C=O) moves to the oxygen 
atom, making it an enol group (-C=C-OH).  
 
 
Figure 4- Keto-enol tautomerism (Wikipedia) 
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2.1.2.2 Stereoisomerism 
Stereoisomers are molecules with the same basic arrangement of their atoms, 
but with different geometrical positioning of atoms and functional groups in 
space. This category includes enantiomers, where isomers are mirror images of 
each other and cis-trans isomers.  
 
A. Cis-trans isomerism 
Cis-trans isomerism, often named geometrical isomers, even if this synonym is 
considered obsolete, describes the orientation of functional groups within the 
molecule (IUPAC Compendium of Chemical terminology). In general, these 
isomers contain double bonds which cannot rotate, or some other feature that 
gives the molecule a certain structural rigidity. In the cis-isomer, the atoms are 
orientated on the same side, in the trans-isomer they are on the opposite side 
(IUPAC Compendium of Chemical terminology) (Figure 5). Cis and trans 
isomers often differ in physical properties, such as melting and boiling points. 
  
 
                                            trans-isomer      cis-isomer 
Figure 5- Cis-trans isomers (http://www.chemguide.co.uk) 
 
 
B. Enantiomers  
Enantiomers are molecules which contain the same number and kinds of atoms 
and bonds, but different spatial arrangements of the atoms. The simplest optical 
isomer has a single carbon atom in its molecule bonded to four different 
functional groups. This carbon atom is called asymmetric carbon or chiral 
centre (Figure 6). 
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Figure 6- Chiral centre 
 
Enantiomers are non-superimposable mirror images of each other, like the left 
and right hand (Figure 7).  
 
 
Figure 7- Enantiomers 
(http://astrobiology.berkeley.edu) 
 
Enantiomers are optical isomers that can rotate the plane of polarised light. If 
the optical isomer rotates the plane of polarised light to the right, it is known as 
(-) or dextrorotatory (D) enantiomer. In contrary, if the optical isomer rotates the 
plane of polarisation to the left, it is called (+) or laevo-rotatory (L) enantiomer.  
The R (R is for rectus, the Latin for right) and S (S is for sinister, the Latin for 
left) notation describes the arrangement of the molecules around the chiral 
centre. The atom of the lowest atomic number is imagined to lie behind the 
plane of the page. The other three atoms lie in the plane of the page and if their 
atomic numbers descend in clockwise direction, it is the R-enantiomer, in 
anticlockwise direction it is the S-enantiomer. They may be laevo- or 
dextrorotatory to polarised light, demonstrating that there is no relationship 
between these classifications. 
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A racemic mixture, or a racemate, is a 1:1 mixture of two enantiomers. A 
racemic mixture has no effect on plane-polarised light, as the amount of 
polarised light rotation caused by the two enantiomers is the same, but in 
opposite direction. 
 
2.2 General anaesthesia in horses 
General anaesthesia in horses is associated with more problems than in other 
species and anaesthetic mortality has always been considered to be relatively 
high, when compared to companion animals or humans (Hall & Clarke 1991a, 
Jones 2001). Most fatalities are related to poor cardiovascular or respiratory 
performances during anaesthesia or to fatal injuries during poor quality 
anaesthetic recovery. 
In 1993, Young and Taylor reported an equine anaesthesia mortality rate of 
0.68%. Ischaemic myopathy, cardiac arrest and bone fractures were found to 
be the main causes of death. Similarly, Mee et al. (1998a) reported a 
surgical/anaesthetic death rate in elective procedures of 0.63%. In horses 
undergoing emergence procedures, mortality was 31.4% (Mee et al. 1998b). 
Horses anaesthetised for surgical colic had a higher mortality rate than animals 
anaesthetised for non-colic emergence procedures.  
Johnston et al. (1995) surveyed a total of 6'225 general anaesthesias in horses 
and reported an overall mortality of 1.6%. When abdominal surgeries and 
deliveries of foals under general anaesthesia were excluded, the mortality rate 
fell to 0.9%. Factors influencing a high mortality were: anaesthesia performed in 
the third trimester of pregnancy, emergence abdominal surgeries, bone 
fractures, administration of xylazine, foals under 1 year old and surgeries 
performed outside normal working hours. The risk of death also increased with 
the duration of anaesthesia. In another survey, the same author studied more 
than 41'000 anaesthesia procedures (Johnston et al. 2002). The overall death 
rate was 1.9%. When emergence abdominal surgery was excluded, the rate fell 
to 0.9%. For abdominal surgery, the rate of mortality was high (11%). Cardiac 
arrest (33%), fractures (25%) and ischaemic myopathy (7%) were defined as 
the most common causes of death.  
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In a more recent retrospective study, the prevalence of fatalities in horses 
directly related to anaesthesia was 0.12% (Bidwell et al. 2007). This incidence 
is lower than that reported in previous studies. Causes of death directly related 
to anaesthesia were cardiac arrest, bone fractures in recovery stall, neuropathy 
and myopathy necessitating euthanasia. Possible explanations for the 
discrepancy from previous studies were the familiarity with the anaesthetic 
protocol, a reduced duration of anaesthesia and an adequate pre-operative 
examination. Horses in which anaesthesia was maintained with volatile agents 
showed higher risk of death than horses in which anaesthesia was maintained 
with total intravenous agents (Johnston et al. 2002). 
In horses more than in other species, maintenance of good intra-operative 
cardiopulmonary function and a calm and coordinated anaesthetic recovery is 
very important.  
 
2.2.1 Cardiovascular effects 
Inhalational anaesthetic agents cause a dose-dependent depression of the 
cardiovascular system. The mechanism of cardiovascular effects includes direct 
myocardial depression and a decrease in sympathoadrenal activity (Tranquilli et 
al. 2007).  
All inhalation anaesthetics decrease cardiac output in a dose-related manner 
due to a decrease in stroke volume as a cause of myocardial depression 
(Tranquilli et al. 2007). Blood pressure is also decreased in a dose-dependent 
manner. Inhalation agents sensitise the myocardium to the arrhythmogenic 
effects of catecholamines. Injectable drugs, such as acepromazine, ketamine 
and alpha2-adrenergic agonists are often administered to horses as part of the 
anaesthetic regimen. These drugs possibly accentuate cardiovascular 
depression (Tranquilli et al. 2007). During equine anaesthesia, 
sympathomimetic drugs such as dopamine and dobutamine are often given at 
low-doses to improve cardiac output and blood pressure (Swanson et al. 1985). 
In horses anaesthetised with halothane, hypercapnia was associated with 
improved cardiovascular function associated with an increase in circulating 
catecholamines (Wagner et al. 1990). 
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The American College of Veterinary Anesthesiologists suggests that for horses 
anaesthetised with inhalant anaesthetics or undergoing anaesthesia lasting 
more than 45 minutes, a continuous electrocardiogram and a blood pressure 
monitor should be employed. Hypotension has to be treated with fluid therapy 
and in severe cases with vasoactive agents such as dobutamine.  
 
2.2.2 Respiratory effects 
Respiratory depression is frequent in anaesthetised horses and can result in 
hypercapnia, hypoxaemia and acid-base abnormalities due to hypoventilation, 
ventilation-perfusion impairment and right-to-left vascular shunts (Kalchofner et 
al. 2009). 
During equine anaesthesia, arterial oxygen tension is lower than might be 
expected from inspired oxygen tension, and thus the alveolar-arterial oxygen 
tension gradient ((A-a)PO2) increases very soon after anaesthesia induction 
(Hall & Clarke 1991a). The arterial oxygen tension (PaO2) partially depends on 
the size of the horse and its position during recumbency (Hall et al. 1968). 
Other factors inducing a large (A-a)PO2 are a reduced cardiac output, 
hypoventilation, intrapulmonary vascular shunts, ventilation/perfusion 
mismatches and atelectasis (Hall & Clarke 1991a). The lung is partially 
collapsed creating atelectasis, probably due to the compression by abdominal 
and thoracic viscera, and may act as a venous-arterial shunt and thus cause 
hypoxaemia (Nyman et al. 1990, Hall & Clarke 1991a). During anaesthesia of 
horses in dorsal or lateral recumbency a shunt developed, independently 
whether the horses were breathing spontaneously or were mechanically 
ventilated (Nyman & Hedenstierna 1989). The shunt was greater in dorsal than 
in lateral recumbency. 
The relationship between ventilation and perfusion is often disturbed during 
equine anaesthesia. Given that ventilation of the lower lung regions of the 
recumbent horse is restricted by limited movements of the diaphragm and rib 
cage, lower lung regions receive more blood than can be oxygenated by the 
prevailing ventilation (Hall & Clarke 1991a). 
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In horses anaesthetised for more than 45 minutes, assisted ventilation may be 
beneficial to reduce the degree of hypercarbia, but the occurrence of 
hypoxaemia cannot be completely avoided. 
 
2.2.3 Recovery 
Recovery is one of the most critical phases of equine anaesthesia and is often 
associated with bone fractures, joint dislocations, haemorrhages, head traumas 
and dehiscences of surgical wounds (Clark-Price et al. 2008). Unfortunately 
anaesthesia recovery is little controllable (Hubbell 2007). Horses may try to 
stand up prematurely and subsequently fall and panic, with the result of further 
attempts to stand with poor results. Ideally, horses regain consciousness within 
20 to 30 minutes after the end of anaesthesia (Bettschart-Wolfensberger, 
personal communication), take briefly sternal position and then stand up 
(Hubbell 2007). As prolonged anaesthesia increases the risk of poor recovery, 
duration of anaesthesia has to be minimised (Auckburally & Flaherty 2009). The 
administration of alpha2-adrenoceptor agonists during recovery from 
anaesthesia prolonged the recovery period but improved its quality without 
producing significant cardiorespiratory effects (Santos et al. 2003). This allows 
volatile agents to be eliminated and permits horses to regain their cognitive 
function before trying to stand (Auckburally & Flaherty 2009). In addition, 
adequate pain relief in form of systemic or local analgesia is very important 
during recovery. Hubbell (2007) presumed that placing horses in a quiet and 
darkened environment improves recovery quality. This could not be 
demonstrated in a prospective randomized clinical trial performed in 29 horses 
(Clark-Price et al. 2008). In that study, no significant differences between 
horses recovering in a darkened stall or in an illuminated environment could be 
detected.  
Horses that fail to rise within reasonable time possibly suffer from post 
anaesthetic myositis (Hubbell 2007). Usually, muscle groups which were on the 
underside of the horse during anaesthesia are affected. The muscles are 
swollen, firm, painful and non-functional (Young 2005). Creatine kinase values 
are elevated (Trim & Mason 1973). Myoglobin may be released in large 
quantities and may result in myoglobinuria with red or red-brown urine. In 
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severe cases, renal failure can occur (Young 2005). The underlying cause of 
post-anaesthetic myopathy is probably ischaemic muscle damage (Young 
2005). The weight of the horses, the non-physiological recumbency during 
anaesthesia, and hypotension during anaesthesia can induce post anaesthetic 
myositis (Schatzmann & Girard 1984). Horses with prolonged halothane-
induced hypotension were more likely to develop post-anaesthetic myopathy 
than horses in which normotension was maintained (Grandy et al. 1987). The 
occurrence of post-anaesthetic myositis may be reduced by using soft surfaces 
to support the recumbent horse and by maintaining mean arterial blood 
pressure above 70 mmHg.  
 
2.2.4 Balanced anaesthesia 
The technique of balanced anaesthesia is based on the concept that the co-
administration of a mixture of small amounts of several drugs shall produce an 
ideal anaesthetic state (Muir & Yamashita 2000). Thus, the advantages, but not 
the disadvantages, of the individual components of the mixture are summated. 
In horses, procedures of longer duration are usually performed under inhalation 
anaesthesia with agents causing a dose-dependent cardiovascular depression 
(Johnston et al. 2002). Ideally, their use should be reduced to a minimal dose 
rate for induction of unconsciousness while the addition of other drugs provide 
analgesia and muscle relaxation. With balanced anaesthesia the quality of 
anaesthesia induction, maintenance and recovery can be improved and the 
need for additional drugs to support cardiac output or arterial blood pressures 
as well as to support recovery can be reduced (Muir & Yamashita 2000). 
Usually used drugs for balanced anaesthesia are lidocaine, ketamine, alpha2- 
adrenergic agonists, opioids and central muscle relaxants.  
 
Lidocaine 
Lidocaine is rapidly metabolised in the liver and has a very short half-life 
(Engelking et al. 1987). In order to achieve constant plasma levels within 
acceptable time, an induction bolus has to be administered followed by a 
constant rate infusion (CRI) (Ringer et al. 2007). Lidocaine administered to 
ponies decreased MAC of halothane in a dose-dependent manner (Doherty & 
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Frazier 1998). In horses undergoing surgery, the requirements for isoflurane 
were reduced by 25% when lidocaine was administered during anaesthesia 
(Dzikiti et al. 2003). The effect of a CRI of lidocaine on the quality of recovery 
from sevoflurane or isoflurane anaesthesia was studied in horses (Valverde et 
al. 2005). Horses that received a CRI of lidocaine had a significantly higher 
degree of ataxia and a lower quality of recovery than horses receiving a saline 
solution. Therefore the authors recommended discontinuing the lidocaine 
infusion 30 minutes before the end of surgery. Another study compared the 
effects of balanced anaesthesia with lidocaine with those of balanced 
anaesthesia with medetomidine (Ringer et al. 2007). Both protocols were 
successfully used to perform surgery. Cardiovascular function was well 
maintained in both groups. However, a more stable depth of anaesthesia and a 
better quality of recovery was observed in horses receiving medetomidine.  
 
Alpha2- adrenergic agonists 
Alpha2-adrenergic agonists are potent analgesics and reduce the MAC of 
inhalant anaesthetic agents. In horses, xylazine administration in isoflurane 
anaesthetised horses reduced the MAC in a dose- and time-dependent manner 
(Steffey et al. 2000). In ponies, mean MAC of desflurane was reduced by 28% 
when inhalation anaesthesia was combined with a CRI of medetomidine 
(Bettschart-Wolfensberger et al. 2001). Cardiopulmonary parameters remained 
stable during the whole anaesthetic episode and the quality of recovery was 
good to excellent. In a retrospective study reporting the use of a CRI of 
medetomidine during isoflurane anaesthesia, 300 equine cases were studied 
(Kalchofner et al. 2006). Only 4 out of 300 horses needed artificial ventilation 
and only one horse had a poor recovery quality. The effects of a CRI of 
dexmedetomidine, the dextrorotatory active enantiomer of medetomidine, were 
studied in isoflurane anaesthetised ponies (Marcilla et al. 2010). No severe side 
effects were observed. Cardiovascular function was well maintained: the typical 
decrease in heart rate was minimal and arterial blood pressure values were 
considered acceptable. However, further studies are necessary to investigate 
the dose-sparing effect of dexmedetomidine CRI. 
 
 
 
17 
 
Ketamine and S(+)-ketamine 
In 1992, Muir and Sams investigated the effects of ketamine on the MAC of 
halothane in horses. The degree of MAC reduction was correlated with plasma 
ketamine concentrations and reached up to 37%. Cardiac output significantly 
increased during ketamine infusions. In comparison to the single use of 
halothane, the concurrent administration of ketamine and guaifenesin allowed 
for a reduced halothane MAC, a more stable anaesthesia and a lower need for 
dobutamine to maintain blood pressure (Spadavecchia et al. 2002). In horses 
receiving an infusion of ketamine and lidocaine in combination with isoflurane, 
the requirements for isoflurane, dobutamine and thiopental were lower than in 
horses receiving isoflurane alone (Enderle et al. 2008). The quality of recovery 
was comparable in both groups. 
Unfortunately, ketamine can induce emergence reactions during the recovery 
period like muscular tremor and rigidity, excitation and ataxia (Muir & Sams 
1992, Larenza et al. 2009). These effects are related to the plasma 
concentrations of ketamine and norketamine and to the length of infusion (Muir 
& Sams 1992). Therefore, the use of racemic ketamine infusion is limited to 
procedures lasting less than 2 hours (Larenza et al. 2009). 
A recent study compared the recovery quality after low doses of racemic and 
S(+)-ketamine in 10 horses (Larenza et al. 2009). Heart rate values before 
surgical stimulation were comparable between both groups, but horses 
receiving racemic ketamine had significantly higher heart rates during surgical 
stimulation, suggesting a stronger analgesic effect of S(+)-ketamine. Horses in 
S(+)-ketamine group had significantly better recovery scores than horses in 
racemic ketamine group. Visual Analogue Scale (VAS) values were positively 
correlated to the length of the infusion in horses receiving racemic ketamine: 
the longer the duration of infusion, the worse was the quality of recovery. In 
horses receiving S(+)-ketamine, no such correlation was evident. 
 
Opioids 
The adjunction of opioids as part of balanced anaesthesia is widespread in 
human and small animal anaesthesia. However, their effect in horses is 
disputed. Opiods are often used in horses to provide analgesia during and after 
surgery and in combination with sedatives for restraint. Most opioids cause a 
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dose-dependent respiratory depression, and excitement and ataxia are frequent 
side-effects (Hall & Clarke 1991a). Morphine, butorphanol and alfentanil did not 
reduce the MAC of inhalant agents in horses (Matthews & Lindsay 1990, 
Pascoe et al. 1993, Steffey et al. 2003). Morphine had an inconsistent influence 
on the MAC of isoflurane, as some horses showed either an increase or a small 
decrease in isoflurane requirements (Steffey et al. 2003). A retrospective 
clinical study evaluated the effects of butorphanol on cardiovascular parameters 
in isoflurane anaesthetised horses (Hofmeister et al. 2008). Butorphanol 
deepened the anaesthetic plane and obtund sympathetic effects following 
surgical stimulation. No adverse effects on heart rate and arterial blood 
pressure were observed. Fentanyl, a synthetic μ-receptor agonist, was 
administered to horses anaesthetised with isoflurane (Thomasy et al. 2006). 
MAC of isoflurane was reduced by 18% at a fentanyl concentration of 13.31 ng 
mL-1. A dose-dependent increase of arterial blood pressures was observed. 
Two horses needed active cooling of the skin to maintain their body 
temperature below 38.6˚C. One horse had a recovery of bad quality, falling 
down several times.  
 
Central muscle relaxants 
Guaifenesin and benzodiazepines can be added to balanced anaesthesia to 
increase muscle relaxation. However, both drug classes will impair recovery by 
causing ataxia during this crucial phase.  
 
2.3 Ketamine and its isomers 
2.3.1 History 
Ketamine is a derivate of phencyclidine and belongs to the group of dissociative 
anaesthetics. It was developed by Parke-Davis in 1962 as part of an effort to 
find a safer anaesthetic alternative to phencyclidine. In 1965, it was tested for 
the first time in twenty volunteers (Domino et al. 1965). It was officially released 
for clinical use in humans in the US in 1970 and became popular as a battlefield 
anaesthetic (Jansen 2000).  
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Ketamine is still widely used in humans. The incidence of its recreational use 
increased through the end of the 20th century. That’s why it is considered as a 
controlled narcotic substance in many countries worldwide.  
In the seventies, racemic ketamine was also registered and marketed for cats. 
Since then, it was widely used as an anaesthetic in veterinary medicine 
because of its large therapeutic window in vertebrates.  
In 1992 the Food and Drug Administration stated that separation of 
stereoisomers had not received appropriate attention and that focussing on this 
issue could open new horizons in therapeutics (Kohrs & Durieux 1998). In the 
late nineties, Pfizer launched Ketanest S®, a product containing the single S(+)-
isomer for use in humans. In 2006, a formulation containing S(+)-ketamine was 
approved for use in cats in Switzerland. 
 
2.3.2 Physicochemical characteristics 
Ketamine is chemically related to phencyclidine (PCP) and cyclohexamine 
(Reich & Silvay 1989) (Figure 8). Its chemical formula is C13H16ClNO and its 
systemic IUPAC name (International Union of Pure and Applied Chemistry) is 
2-(2-chlorophenyl)-2-methylamino-cyclohexanone.  
 
Figure 8- Molecular structure of ketamine (www.lookchem.com) 
 
Ketamine has a molecular weight of 238 and a pKa of 7.5 (White et al. 1982). 
Although ketamine hydrochloride is water-soluble, ketamine has a high lipid 
solubility, ten times that of thiopentone (Reich & Silvay 1989). pH value of 
watery ketamine is between 3.5 and 5.5. Therefore tissue irritation may occur 
after intramuscular administration (Booth 1988).  
Ketamine contains a chiral centre at the C2-carbon of the cyclohexanone ring 
and therefore, two enantiomers exist: S(+)-ketamine and R(-)-ketamine (Reich 
& Silvay 1989) (Figure 9). The most widely commercially available ketamine 
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preparations contain a racemic mixture of the two enanatiomers, but the pure 
S(+)-enantiomer is also registered for clinical use in humans and cats. 
 
  S(+)-ketamine hydrochloride        R(-)-ketamine hydrochloride 
 
Figure 9- Ketamine enantiomers  
 
2.3.3 Pharmacokinetics 
Ketamine can be applied intramuscularly, subcutaneously and intravenously. 
Rectal, oral and nasal applications have also been described in humans (Ĉetina 
1982, Paddleford & Erhardt 1992, Adams & Werner 1997), which made 
ketamine a popular drug in emergence medicine. Due to extensive first pass 
metabolism, plasma levels of ketamine are low after oral administration.  
After parenteral administration, ketamine is rapidly absorbed. After a single 
intravenous administration, the highest ketamine plasma concentration is 
achieved after one minute in most species and within five to ten minutes 
following an intramuscular administration (Kaka et al. 1979, White et al. 1982, 
Waterman 1984, Adams & Werner 1997, Pypendop & Ilkiw 2005, Larenza et al. 
2007).  
Ketamine is first distributed in high-perfused tissues, including the brain. 
Because of its high lipid solubility, ketamine penetrates the blood brain barrier 
fast and develops its effects on the central nervous system (CNS) after a very 
short period of time (Cohen & Trevor 1974). The highest concentration in the 
brain is 4 to 6.5 times higher than that of the plasma (White et al. 1982, Adams 
& Werner 1997). This initial distribution from the central compartment (plasma) 
to peripheral tissues occurs with a half-life of 7 to 11 minutes (White et al. 
1982). Subsequently, ketamine is redistributed from well-perfused tissues to 
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less perfused tissues. This redistribution has been found responsible for 
termination of the hypnotic and anaesthetic effects (Cohen & Trevor 1974, 
White et al. 1982). Ketamine is not strongly bound to plasma proteins (Kaka et 
al. 1979, Hanna et al. 1988a).  
Ketamine is extensively metabolised in the liver. Cytochrome P450 enzymes are 
involved in the metabolism of racemic ketamine. Ketamine is n-demethylated to 
norketamine. Norketamine possesses approximately 1/3 of the effect of the 
original compound (Craven 2007, Gehring et al. 2009). Norketamine is further 
hydroxylated to hydroxy-norketamine and then conjugated to a more water-
soluble glucuronide derivate (5-6- dehydronorketamine) that is finally eliminated 
with the urine (Chang & Glazko 1974, White et al. 1982). Approximately 5% is 
eliminated with the faeces. The elimination half-life ranges between 1 to 3 hours 
(White et al. 1982, Hanna et al. 1988b, Adams & Werner 1997, Kohrs & Durieux 
1998). 
 
Stereoselective pharmacokinetics 
Equianaesthetic doses of 1 mg kg-1 S(+)-ketamine, 2 mg kg-1 racemic ketamine 
and 3 mg kg-1 R(-)-ketamine were administered to human patients (White et al. 
1980). The dose-response curves of norketamine and the metabolite of 
norketamine were qualitatively identical among the three treatment regimens, 
indicating that there were no major differences in the pharmacokinetic 
properties of the enantiomers which could be attributed to stereospecificy. 
However, a higher clearance was found for S(+)-ketamine, when compared to 
the racemate and R(-)-ketamine. In vitro data suggest that human microsomes 
n-demethylate S(+)-ketamine at a higher rate than R(-)-ketamine (Henthorn et 
al. 1999, Ihmsen et al. 2001). Ihmsen et al. (2001) also demonstrated that if 
racemic ketamine is used, the elimination of S(+)-ketamine is more rapid than 
that of R(-)-ketamine, but is inhibited by R(-)-ketamine. In the same way, in vitro 
biotransformation of ketamine in equine liver and lung occurs with a slower 
elimination of S(+)-ketamine in the presence of R(-)-ketamine (Schmitz et al. 
2008).  
Two stereoselective pharmacokinetic studies were performed in Shetland 
ponies (Larenza et al. 2007, Larenza et al. 2008a). In the first study, ponies 
were anaesthetised with isoflurane and were then administered either 2.2 mg 
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kg-1 racemic ketamine or 1.1 mg kg-1 S(+)-ketamine intravenously (Larenza et 
al. 2007). The pharmacokinetic parameters of R(-)- and S(+)-ketamine did not 
significantly differ. But plasma concentrations of S(+)-norketamine were higher 
than plasma concentrations of R(-)-norketamine in the racemic group. This 
result suggests that in the presence of isoflurane, the metabolism of racemic 
ketamine is highly stereoselective. In the second study, 2.2 mg kg-1 racemic 
ketamine or 1.1 mg kg-1 S(+)-ketamine was administered intravenously in 
ponies previously sedated with xylazine (Larenza et al. 2008a). Plasma 
concentrations of S(+)-norketamine were statistically different between both 
groups at three different time-points. Distribution of ketamine was not 
enantioselective. The first-order elimination rate for S(+)-ketamine was higher, 
while elimination half-life and mean residual time were lower in the S(+)-
ketamine group, when compared to the racemic ketamine group. These results 
suggest that S(+)-ketamine elimination might be favoured when given alone. In 
addition, ponies receiving the S(+)-isomer stood up faster than ponies receiving 
the racemic mixture. 
 
2.3.4 Pharmacodynamics 
 
2.3.4.1 Molecular pharmacodynamics 
The molecular pharmacodynamics of ketamine is complex. It interacts with 
multiple binding sites, including N-methyl D-aspartate (NMDA) and non-NMDA 
glutamate receptors, nicotinic and muscarinic cholinergic, monoaminergic and 
opioid receptors (Kohrs & Durieux 1998). In addition, interactions with voltage-
dependent ion channels such as Na+ and Ca2+ channels have been described 
(Wong & Martin 1993). All of these interactions may play a role in ketamine’s 
pharmacological and clinical properties, but NMDA receptor antagonism is 
responsible for most of the analgesic, amnestic, psychomimetic and 
neuroprotective effects of the agent (Kohrs & Durieux 1998).  
The NMDA receptor (Figure 10) is an ionotropic receptor that is activated by 
glutamate, the most important excitatory neurotransmitter in the central nervous 
system (Kohrs & Durieux 1998). The channel is permeable to Ca2+ and, to a 
lesser extent, to Na+ and K+. Glycine is an obligatory co-agonist and Mg2+ 
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inhibits the channel in a voltage-dependent manner. NMDA receptors are 
involved in the wind-up phenomenon and probably play a major role in the 
development of chronic pain (Woolf 1989, Ilkjaer et al. 1996, Kress 1997).  
Ketamine binds to the phencyclidine receptor in the NMDA channel and thus 
inhibits non-competively the glutamate activation (Kohrs & Durieux 1998).  
 
 
Figure 10- NMDA receptor (www.uochb.cz) 
 
S(+)-ketamine has a three- to fourfold higher affinity for the phencyclidine 
binding site of the NMDA-receptor than the R(-)-enantiomer (Oye et al. 1992, 
Adams & Werner 1997, Kress 1997, Kohrs & Durieux 1998). 
Non-NMDA glutamate receptors were demonstrated to be inhibited by ketamine 
(Gonzales et al. 1995). The effects are probably mediated through the 
glutamate/NO/cGMP system (Kohrs & Durieux 1998). Nitric oxide plays a role 
as neurotransmitter centrally and peripherically, and increases the intracellular 
cGMP production (Kress 1997). The NO synthase inhibition induced by 
ketamine may be involved in its analgesic effects (Gordh et al. 1995, Kohrs & 
Durieux 1998).  
Ketamine also interacts with mu (μ), delta (δ) and kappa (κ) opioid receptors. Its 
affinity for these receptors is highest for μ, and lowest for δ receptor, and is 10 
to 20 times less than for the NMDA channel. S(+)-ketamine has a two- to 
fourfold higher affinity to μ and κ opioid receptors than R(-)-ketamine (Kress 
1997, Kohrs & Durieux 1998). The interaction of ketamine with opioid receptors 
seems not to be of major clinical importance (Kohrs & Durieux 1998), but a role 
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of κ opioid receptors in the occurrence of psychomimetic side effects seems to 
be established (Finck & Ngai 1982, Kohrs & Durieux 1998).  
Ketamine also affects nicotinic and muscarinic acetylcholine receptors by 
inhibiting NMDA receptor-mediated acetylcholine release (Kress et al. 1997, 
Kohrs & Durieux 1998). In comparison to R(-)-ketamine, the S(+)-enantiomer 
shows a twofold stronger affinity for the muscarinic receptor (Kress et al. 1997). 
The affinity for this receptor is 10 to 20 times less than the binding to NMDA 
receptor (Kohrs & Durieux 1998). As seen for opioid receptors, emergence side 
effects during recovery phase may be partly related to the inhibition of the 
cholinergic transmission by ketamine (Kohrs & Durieux 1998).  
Both ketamine enantiomers inhibit the neuronal uptake of noradrenaline, and 
S(+)-ketamine additionally inhibits the extraneuronal uptake (Adams & Werner 
1997, Kress 1997). 
Interactions with voltage-dependent ion channels have also been described 
(Kohrs & Durieux 1998). Inhibition of Na+ channel function plays a role in the 
local application of ketamine, i.e. epidural injection (Kress 1997). 
Gamma-amino-butyric receptors (GABA) are the most common inhibitory 
neurotransmitter in the central nervous system (Kohrs & Durieux 1998). 
Ketamine seems to have some effect on GABA receptors, but only in 
concentrations higher than those used for clinical purposes.  
 
2.3.4.2 Effects on the cardiovascular system 
The cardiovascular activity of ketamine results of different indirect stimuli of the 
heart: sympathomimetic effects mediated within the central nervous system, 
inhibition of neuronal uptake of catecholamines by sympathetic nerve endings, 
direct vasodilatation of vascular smooth muscle and an inotropic effect on the 
myocardium (Muir & Hubbell 1988, Lin 2007).  
Both, racemic ketamine and S(+)-ketamine, cause a dose dependent 
stimulation of heart rate and arterial blood pressures as well as an increase in 
cardiac output. These effects are caused by direct sympathomimetic activation 
(White et al. 1982, Adams & Werner 1997, Zielmann et al. 1997) and are 
particularly pronounced after the single use of ketamine. Studies in humans 
demonstrated that the administration of 2 mg kg-1 racemic ketamine or 1 mg  
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kg-1 S(+)-ketamine causes a comparable increase in heart rate and arterial 
blood pressure (Adams et al. 1992). In another study conducted by Doenicke et 
al. (1992a) in 30 healthy volunteers, no differences were found between 
racemic and S(+)-ketamine, as well. Different catecholamine levels were 
detected after administration of either racemic or S(+)-ketamine: epinephrine 
clearly increased after racemic ketamine administration, whilst only a slight 
variation occurred with the isomer (Doenicke et al. 1992b). However, 
norepinephrine levels similarly increased in both groups. The combined use 
with benzodiazepines prevented the centrally mediated sympathetic effects of 
ketamine on the heart. Therefore this combination is recommended in cardiac 
risk patients. 
In horses, the clinical use of racemic ketamine was compared with S(+)-
ketamine (Filzek et al. 2003). Horses were premedicated with xylazine and 
guaifenesin. Anaesthesia was induced with either 3 mg kg-1 racemic ketamine 
or 2 mg kg-1 S(+)-ketamine. Five repetitive xylazine/racemic ketamine, 
respectively xylazine/S(+)-ketamine doses were given intravenously to prolong 
anaesthesia. Both groups showed a decrease in heart rate, probably due to the 
administration of xylazine. In contrary to findings in humans, mean arterial 
blood pressure was higher in horses treated with S(+)-ketamine when 
compared to horses treated with the racemate.  
At high doses (30 mg kg-1), ketamine and its isomers induced a transient but 
significant cardiac depression for 15 minutes in dogs. Values returned to 
baseline values by 20 minutes after ketamine administration. No differences in 
the cardiopulmonary effects were noticed between ketamine or its isomers 
(Muir & Hubbel 1988).  
Myocardial stimulation is associated with increased cardiac work and 
myocardial oxygen consumption (Lin 2007). 
The direct effect of ketamine on the myocardium is controversial. The findings 
in vivo are not consistent with those reported in vitro (Graf et al. 1995, Adams & 
Werner 1997). Investigations with denervated heart preparations have 
demonstrated a dose-dependent depressant effect of ketamine on myocardial 
contractility (White et al. 1982, Lin 2007). On the isolated guinea pig heart, 
S(+)-ketamine had a significantly lesser cardiac depressant effect than did R(-)-
ketamine (Graf et al. 1995). This finding was attributed to an increased 
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availability of catecholamines. However, in vivo the centrally acting effects of 
ketamine outweighed its depressing effect on the myocardium.  
 
2.3.4.3 Effects on the respiratory system 
At usual clinical doses, ketamine has little effect on the respiratory system and 
causes minimal respiratory depression with only mild hypercapnia (Kohrs & 
Durieux 1998). In human patients suffering from asthma, ketamine is often used 
as an induction agent, because it reduces the airway resistance. In dogs, 
respiratory rate and minute volume decrease initially, but return to baseline 
values within 15 to 20 minutes (Haskins et al. 1985). Severe respiratory 
depression after an overdose has been reported in humans and felines (Lin 
2007). If administered rapidly by intravenous injection, ketamine often induces a 
transient apnea. As it crosses the placental barrier (Hall & Clarke 1991b), 
respiratory depression may occur in the foetus (Adams & Werner 1997). 
Ketamine has a bronchodilatory effect (Reich & Silvay 1989), and pharyngeal 
and laryngeal reflexes are maintained (Lin 2007). Salivation and respiratory 
tract secretions increase after administration of ketamine. Care should always 
be taken to prevent airway obstruction or aspiration (Lin 2007). No differences 
between the isomers have been described in literature. 
 
2.3.4.4 Effects on the central nervous system (CNS) 
Ketamine produces a dose-dependent central nervous system depression that 
leads to a "dissociative anaesthetic state" causing a catalepsy-like state, 
amnesia and profound analgesia. The mechanism of action suggests a 
functional and electrophysiological dissociation between the thalamocortical 
and the limbic systems (White et al. 1982, Kohrs & Durieux 1998). On 
molecular level, NMDA-receptor antagonism plays a major role in the 
mechanism of action of ketamine in the CNS.  
In human patients, hallucinations and psychotomimetic reactions following 
ketamine anaesthesia may occur during recovery phase (Craven 2007). Mood 
alterations, extracorporeal experiences, floating sensations, illusions, and even 
delirium have also been described (White et al. 1982). A possible explanation 
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for the hallucinations and illusions is a ketamine-induced depression of the 
auditory and visual nuclei whereas the out-of-body experiences and floating 
sensations may be explained by the loss of skin and musculoskeletal 
sensations (White et al. 1982). When used in patients suffering from 
schizophrenia, ketamine may reactivate psychoses (Craven 2007). Therefore 
its use should be avoided in psychotic patients. 
Ketamine has both pro- and anticonvulsant properties (Craven 2007). At low 
doses, ketamine may have anticonvulsant properties through antagonism of 
NMDA receptors (Reder et al. 1980). In some animal models, ketamine was 
effective in controlling recalcitrant seizures (Manno 2003). Some cases of 
human patients treated successfully in refractory status epilepticus have been 
described (Prüss & Holtkamp 2008, Varelas & Spanaki 2010). However, the 
occurrence of seizures in association with the administration of ketamine has 
been reported in dogs and cats (Mori et al. 1971, Lin 2007). Therefore, the risk-
benefit-ratio of the use of ketamine in animals with a history of seizures or 
epilepsy should be assessed carefully.  
Ketamine has been demonstrated to increase cerebral blood flow (CBF), 
intracranial pressure (ICP) and cerebrospinal fluid pressure as a result of 
cerebral vasodilatation and elevated systemic blood pressure (Lin 2007). 
However, the mechanism of action of ketamine on ICP is controversial. Some 
studies did not demonstrate any adverse effects of ketamine on CBF and ICP 
(Craven 2007). Most probably, differences in ventilation strategies may explain 
earlier findings (Schmidt et al. 2008). Independent of the pre-existing ICP, 
ketamine did not increase ICP when normocapnia was maintained with 
controlled ventilation (Pfenninger et al. 1984). In piglets with pre-existing 
intracranial hypertension, administration of ketamine caused an increase in 
both ICP and pCO2 (Pfenninger et al. 1985). The ICP rise seems to be 
secondary to the hypercapnia. As a result of these studies it has been 
suggested that controlled ventilation should always be initiated when ketamine 
is administered to patients with intracranial disease (Lin 2007). 
Neuroprotective and neuroregenerative effects of ketamine have been 
discussed recently. Ketamine, administered post-injury, has been demonstrated 
to have neuroprotective effects (Himmelseher et al. 1996). Post-ischemic 
administration of S(+)-ketamine had a positive influence on oxygen saturation 
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and cortical neuronal cell death after global forebrain ischemia (Proescholdt et 
al. 2001). In rat hippocampal neurons, neuroregenerative properties were 
demonstrated by S(+)-ketamine, but not by the racemate (Himmelseher et al. 
1996). 
 
2.3.4.5 Analgesic effects 
Sub-anaesthetic doses of ketamine produce a dose-dependent analgesia in 
humans and animals (Ryder et al. 1978, Finck & Ngai 1982, Arendt-Nielsen et 
al. 1996, Ilkjaer et al. 1996, Wagner et al. 2002). The degree of analgesia 
appears to be greater for somatic than for visceral pain (Haskins et al. 1985, Lin 
2007).  
In humans, rats and mice, the analgesic potency of S(+)-ketamine was reported 
to be twice that of the racemic mixture and four times that of the R(-)-isomer 
(Ryder et al. 1978, Mathisen et al. 1994, Arendt-Nielsen et al. 1996, Oye et al. 
1992, Kohrs & Durieux 1998).  
NMDA receptors are involved in hyperalgesic responses after tissue injuries. 
Hyperalgesia occurs when nociceptors are sensitised by an inflammatory 
response that reduces the threshold level of neuronal excitability. It is presumed 
that ketamine may be effective at reducing hyperalgesia (Lin 2007). In vivo, low 
doses of S(+)-ketamine applied before a high-frequency stimulation, blocked 
the long-term potentiation in the rat spinal cord (Benrath et al. 2005). The 
combined use with fentanyl induced a reduction of C-fibre evoked potentials 
and prevented long-term potentiation in pain pathways. In inhibiting central 
summation of pain in men, S(+)-ketamine was approximately twice as potent 
than ketamine racemate (Arendt-Nielsen et al. 1996). In horses, pre-emptive 
epidural ketamine reduced post-incisional pain (Rédua et al. 2002). In dogs 
undergoing forelimb amputation, peri-operative treatment with low doses of 
ketamine was associated with a slightly improved postoperative period, 
suggesting an analgesic effect (Wagner et al. 2002). An antinociceptive effect 
of ketamine, demonstrated as a depression of the nociceptive withdrawal reflex, 
was detected after a constant rate infusion in standing Shetland ponies 
(Knobloch et al. 2006, Peterbauer et al. 2008). In the study of Peterbauer et al. 
(2008), antinociceptive effects failed to be demonstrated after administration of 
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S(+)-ketamine. This lack of effect may be explained by the fact that S(+)-
ketamine plasma levels after racemic ketamine administration were 
considerably higher than in ponies receiving S(+)-ketamine. 
 
2.3.4.6 Anaesthetic and post-anaesthetic emergence effects  
Ketamine is a dissociative anaesthetic commonly used in humans and animals. 
It has also been reported to produce local anaesthesia (Hirota & Lambert 
1996). In humans, it is clinically used for indications such as induction of 
anaesthesia in haemodynamically compromised patients, induction of 
anaesthesia in patients suffering from asthmatic disease, anaesthesia for short, 
painful surgeries such as dressing changes in burn patients, intramuscular 
induction in non-cooperative patients and children and supplementation of 
incomplete regional or local anaesthesia (Hempelmann & Kuhn 1997, Kohrs & 
Durieux 1998). In animals, ketamine has been shown to reduce requirements 
for inhalant anaesthetics, and therefore it is commonly used for balanced 
anaesthesia (Pypendop & Ilkiw 2005). 
In rats and mice, S(+)-ketamine has a 1.5 to 3-fold greater hypnotic potency 
than the R(-)-isomer (Ryder et al. 1978, White et al. 1980). The calculated index 
of S(+)-ketamine is greater than that of racemic ketamine and the R-isomer 
(Marietta et al. 1977). In humans, S(+)-ketamine induced the same depth of 
anaesthesia with only half of the dose of racemic ketamine (Doenicke et al. 
1992a). In cats, the S(+)-isomer has been proven to be advantageous over 
racemic ketamine in obtaining an identical depth of anaesthesia with only 60% 
of the racemic dose (Wiederstein & Auer 2003). In a study performed in dogs, 
the anaesthetic potency between racemic ketamine and S(+)-ketamine was 
1:1.29 (Duque et al. 2008). Deleforge et al. (1991) demonstrated that S(+)-
ketamine was three times more potent than the R(-)-isomer in dogs. In horses, 
only 2/3 of the racemic dose was necessary to maintain equivalent levels of 
anaesthesia with S(+)-ketamine (Filzek et al. 2003). In another study, horses 
were anaesthetised with either 2 mg kg-1 racemic ketamine or 2 mg kg-1 S(+)-
ketamine in combination with diazepam (Rossetti et al. 2008). S(+)-ketamine 
was found to be advantageous over racemic ketamine by requiring less 
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anaesthetic agents during surgery and by showing a better overall recovery 
quality.  
Emergence from ketamine anaesthesia is dose-dependent and can be 
complicated by the occurrence of unpleasant psychotomimetic reactions (Kohrs 
& Durieux 1998). Nausea and vomiting, alterations in mood state, amnesia, 
dissociative or out-of-body experiences, floating sensations, nightmares, 
illusions and delirium have been described in humans (White et al. 1982, Kohrs 
& Durieux 1998). Therefore, its combination with benzodiazepines is 
recommended. In volunteers, S(+)-ketamine was associated with a more rapid 
recovery of vigilance (White et al. 1985). Even if no difference in the frequency 
of dreams was observed, patients felt more comfortable after S(+)-ketamine 
(Doenicke et al. 1992a) and a larger proportion of patients would accept a 
repeat anaesthesia with S(+)-ketamine compared to racemic ketamine (85% vs. 
65%) (White et al. 1980). In cats and horses, anaesthesia with S(+)-ketamine 
was also associated with an overall better recovery quality (Filzek et al. 2003, 
Larenza et al. 2008b, Rossetti et al. 2008, Larenza et al. 2009).  
 
3. MATERIALS AND METHODS 
3.1. Study design and animal selection 
The present study was performed to support the data on clinical efficacy for the 
registration of S(+)-ketamine, a new medicinal product for use in horses. 
Originally, it was planned to compare a CRI of racemic ketamine with a CRI of 
S(+)-ketamine in isoflurane anaesthetised horses. Therefore, a pilot study 
comparing the effects on recovery quality of a CRI of racemic ketamine with a 
CRI of the single S(+)-isomer was performed in 10 horses (Larenza et al. 
2009). The results of this preliminary study showed that recovery in horses 
anaesthetised with a CRI of ketamine racemate was of low quality, and the risk 
for the horses to get injured was considered too high for further evaluation. 
Therefore, it was decided to adapt the study design. Scientific advice prior to 
submission of the application for a marketing authorisation was thus requested 
from the Swiss Agency of Therapeutic Products (Swissmedic). After 
consultation with Swissmedic it was decided to compare the CRI of S(+)-
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ketamine with the standard anaesthesia protocol from the University of Zurich 
using a CRI of medetomidine and racemic ketamine as an induction agent. 
Horses allocated to the Med group were therefore anaesthetised with racemic 
ketamine, whereas in horses allocated to the S-ket group, anaesthesia was 
induced with S(+)-ketamine as part of a completely new anaesthetic protocol. 
The experiment was performed with the permission of the local Committee for 
Animal Experimentation. The study was conducted as a randomised, blinded, 
prospective clinical trial according to the Good Clinical Practice (GCP) 
guidelines. In total, 50 horses (16 mares, 19 stallions and 15 geldings), with a 
mean ± SD weight of 524 ± 97 (260 – 725) kg entered the study. Horses were 
aged between one and eighteen (7.7 ± 4.7) years. The horses were randomly 
allocated to two groups, containing 25 animals each: "Med group" and "S-ket 
group". Horses in Med group received a constant rate infusion (CRI) of 
medetomidine and horses in S-ket group received a CRI of S(+)-ketamine as 
part of a balanced anaesthetic regimen with isoflurane. The anaesthetist 
remained unaware of the group allocation.  
Prior to anaesthesia induction, a careful physical examination was performed. 
Body weight, heart rate, respiratory rate, body temperature, mucous membrane 
colour, capillary refill time, pulse character and thoracic auscultation were 
assessed. Furthermore, haematocrit and plasma total proteins were analysed. 
Horses were classified according to the American Society of 
Anaesthesiologists’ (ASA) physical status classification in ASA risk groups I to 
V. After careful clinical examination, they were included in the study if they 
matched following criteria: ASA I, II or III patients, horses undergoing elective 
surgery in every part of the body but the head or neck region, patients that were 
expected to recover from anaesthesia without assistance and patients with 
physiological heart arrhythmias only. On the other hand, patients allocated to 
ASA IV or V, horses with pre-anaesthetic pathological cardiovascular or 
haemodynamic disorders, pregnant mares, patients undergoing surgery of the 
head or neck region, horses with severe fractures or orthopaedic conditions that 
were expected to require assisted recovery, emergency patients or non-
cooperative animals that required intramuscular sedation were excluded from 
the study. 
 
 
32 
 
3.2 Animal management and housing 
Until anaesthesia induction, the horses were housed individually in conventional 
boxes at the stables of the Equine Clinic of the Vetsuisse Faculty in Zurich. 
Their owners were informed on the trial procedures and general anaesthesia 
risks and requested to sign a consent form. Immediately after surgery and until 
complete recovery of motor function, the horses were placed into a padded box 
until their release. During anaesthesia induction and recovery, the horses wore 
a protective helmet and bandages on their extremities. During the recovery 
phase, oxygen was provided through a nasal tube until achieving sternal 
position.  
 
3.3 Animal feeding 
The horses were fed according to their medical condition. Eight to sixteen 
hours before surgery, food was withheld to avoid the hazards of food 
aspiration after anaesthesia induction and to reduce the effects of intra-
operative tympanism that may interfere with free movement of diaphragm 
and perturb breathing. As excessive fasting can encourage gut stasis and 
therefore increase the risk of post-anaesthetic colic (Hall & Clark 1991c), the 
horses were not starved for a longer time period. Free access to water was 
provided until half an hour prior to anaesthesia induction and after complete 
recovery from anaesthesia. 
 
3.4 Treatments 
The same anaesthetist, who was unaware of the group allocation, performed all 
anaesthetic episodes.  
 
Anaesthesia Induction 
A 14-gauge x 16 mm over the needle catheter (Secalon® T with flowswitch, 
Becton Dickinson AG, Basel, Switzerland) was placed into the jugular vein after 
skin desensitization with 2 mL mepivacaine 2%. Thirty minutes before 
anaesthesia induction, patients in both groups received an intravenous injection 
of 35'000 IU kg-1 penicilline sodium (Penicilline Natrium Streuli 10 Mio UI ad us. 
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vet., G. Streuli & Co AG, Uznach, Switzerland), 7 mg kg-1 gentamicine 
(Vetagent® ad us. vet., Injektionslösung, Veterinaria AG, Zurich, Switzerland) 
and 1 mg kg-1 bodyweight flunixin meglumine (Fluniximin® ad us. vet., 
Injektionslösung, Dr. E. Graeub AG, Bern, Switzerland) and an intramuscular 
injection of 0.03 mg kg-1 acepromazine (Prequillan® ad us. vet., 
Injektionslösung, Arovet AG, Zollikon, Switzerland). Patients were relocated to 
the surgical suite. All horses received an intravenous dose of 7 µg kg-1 
medetomidine (Domitor® ad us. vet., Injektionslösung, Pfizer AG, Zurich, 
Switzerland) as a slow bolus over 2 minutes. Approximately 7 to 10 minutes 
after medetomidine injection, and when sedative effects were achieved, the 
horses received 0.03 mg kg-1 of intravenous midazolam (Dormicum® Ampullen, 
Roche Pharma AG, Reinach, Switzerland) followed by a rapid intravenous 
bolus of either 1.1 mg kg-1 S(+)-ketamine (Keta-S® ad us. vet., Injektionslösung, 
Dr. E. Graeub AG, Bern, Switzerland) for patients in the S-ket group or 2.2 mg 
kg-1 racemic ketamine (Ketasol ad us. vet., Injektionslösung, Dr. E. Graeub AG, 
Bern, Switzerland) for patients in the Med group. 
 
To preserve blinding of the study, an assistant veterinarian prepared all 
induction agents, which were diluted with physiologic saline solution up to a 
final volume of 20 mL. After induction of anaesthesia, horses were intubated 
with a cuffed rubber-silicone tube and connected to a large animal anaesthesia 
machine via a large animal circle system. Anaesthesia was maintained with 
isoflurane (Isoflo® ad us. vet., Inhalationsanästhetikum, Abbott AG, Baar, 
Switzerland) in oxygen (3 - 5 L min-1, Fi'O2 around 0.7) to an initial end-tidal 
concentration of 1.2%. They were then positioned on the surgical table in lateral 
or dorsal recumbency, depending on the surgical approach. A catheter was 
placed in the urinary bladder of all horses. 
 
Anaesthesia maintenance  
The lungs of the horses were mechanically ventilated to maintain the end-tidal 
carbon dioxide pressure between 45 and 55 mmHg. Isoflurane delivery was 
always adjusted by the same experienced anaesthetist to the minimal end-tidal 
concentration (FE'iso) required to prevent the horse from moving, muscle 
rigidity or nystagmus and to maintain corneal or blinking reflexes. If sudden 
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movements or nystagmus occurred during anaesthesia, a bolus of 0.1 to 0.5 
mg kg-1 thiopental (Pentothal®, Ospedalia AG, Hühnenberg, Switzerland) was 
administered intravenously. The total administered amount of thiopental was 
recorded. 
An infusion of 10 mL kg-1 hour-1 of lactated Ringer's solution (RLS) (Ringer-
Lactat Lösung, Fresenius Kabi AG, Stans, Switzerland) was delivered during 
the entire anaesthetic procedure through the jugular catheter. The patients in 
the S-ket group received a constant rate infusion (CRI) of 0.5 mg kg-1 hour-1 
S(+)-ketamine and those in the Med group a CRI of 3.5 µg kg-1 hour-1 
medetomidine through the jugular catheter. The RLS line was connected to a 
three-port stop cock which allowed for other supportive drug administration (i.e. 
dobutamine). This stop cock was connected to an extension tube which in turn 
was connected to two three-way stop cocks in parallel, one for the CRI delivery 
and the other one for lithium/thiopental administration. In order to avoid 
retrograde administration of solutions or drugs, unidirectional flow-valves were 
placed in between the above-mentioned stop cocks and extensions.  
S(+)-ketamine and medetomidine CRIs were administered by use of a syringe 
infusion pump (Phoenix 700, Schoch electronics, Möriken, Switzerland), each 
via a 2 x 1.5-m-long (total volume: 6 mL) non-distensible extension tube 
connected to the intravenous catheter by the proximal three-way valve. To 
ensure accuracy in calculation of the infused volumes of S(+)-ketamine and 
medetomidine, the extension tubes were filled with 6 mL of drug solution and 
the initial volume contained in the syringe was recorded. At the end of the 
procedure, the infused volume of drug was calculated from the initial volume 
minus the volume that remained in the syringe. Medetomidine (1 mg mL-1) and 
S(+)-ketamine (60 mg mL-1) were diluted in physiologic saline (0.9% NaCl) 
solution to a working concentration of 0.1 mg mL-1  and 14.3 mg mL-1, 
respectively. 
 
Anaesthesia monitoring 
A 18-gauge cannula (Surflo® IV Catheter 22G x 1", Terumo®, Medical Solution 
GmbH, Cham, Switzerland) was inserted into a facial artery and connected via 
a non-distensible extension tube filled with heparinized saline to an electronic 
pressure transducer. The transducer was placed and zeroed at the level of the 
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shoulder for horses placed in dorsal recumbency or at the level of the sternal 
manubrium for horses placed in lateral recumbency. Systolic (SAP), diastolic 
(DAP) and mean (MAP) arterial blood pressures were obtained. Oxygen 
saturation (SpO2) was obtained via a pulse oximetry infrared probe placed 
around the tongue. A lead II electrocardiogram (ECG) was displayed, and heart 
rate (HR) was calculated. Inspired oxygen fraction (Fi'O2), end-tidal isoflurane 
concentration (FE'iso) and end-tidal carbon dioxide partial pressure (PE'CO2) 
were obtained from a side-stream gas sampler plugged to a port placed at the 
bifurcation of the Y-piece of the breathing system. Respiratory rate (RR) was 
calculated from the capnogram. All data was continuously measured with a 
monitor (Datex S5, Helsinki, Finland) and recorded every 5 minutes. Prior to 
each anaesthetic episode, the monitor was calibrated with a standardized 
calibration gas according to the manufacturers’ instructions. Values for peak 
inspiratory pressure were obtained from a manometer placed within the 
ventilator. 
Arterial blood samples were anaerobically collected into syringes containing 
heparin and analysed immediately. Arterial blood pH, partial pressure of oxygen 
(PaO2), partial pressure of carbon dioxide (PaCO2), bicarbonate concentration 
(HCO3-), total carbon dioxide concentration (TCO2), base excess (BE), 
haemoglobin concentration (Hb) and haemoglobin oxygen saturation (SaO2) 
were assessed by use of a blood gas machine (i-STAT analyzer and G3+ 
cartridges, Axon Lab AG, Baden-Dättwil, Switzerland).  
The degree of impairment of alveolar oxygen exchange was estimated with the 
PaO2/Fi'O2 index. 
 
Treatment of intra-operative hypotension/hypertension and hypoxaemia 
Dobutamine (Dobutrex®, Eli Lilly S.A., Geneva, Switzerland) was diluted in a 
saline (NaCl) solution plus 5% glucose to a final concentration of 1 mg mL-1. 
After anaesthesia induction, an initial dobutamine infusion was started at a dose 
rate of 0.01 mg kg-1 hour-1 and subsequently adjusted to keep a target mean 
arterial pressure (MAP) between 70 and 100 mmHg.  
If MAP was below 70 mmHg, the dobutamine infusion rate was increased by 
0.01 mg kg-1 hour-1 every 5 minutes until target MAP was reached. In contrast, 
if MAP was above 100 mmHg, the infusion rate was reduced by 0.01 mg kg-1 
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hour-1 every 5 minutes, or discontinued if the rate was already 0.01 mg kg-1 
hour-1, until target MAP was reached. At the end of the procedure, the total 
dose rate of dobutamine was calculated.  
If intra-operative PaO2 fell below 70 mmHg, salbutamol (Ventolin® Dosier-
Aerosol, GlaxoSmithKline AG, Münchenbuchsee, Switzerland) was delivered 
through the endotracheal tube at a dose of 2 µg kg-1 every 20 minutes until a 
PaO2 ≥ 70 mmHg was achieved. The total dose of salbutamol to provide a 
PaO2 ≥ 70 mmHg was calculated at the end of the procedure. 
 
Cardiac output (CO) and cardiac index (CI)  
Cardiac output was measured 20, 45, 85, 150 and 210 minutes after 
anaesthesia induction, if the length of anaesthesia allowed for it, using the 
lithium dilution technique (LiDCO) (Linton et al. 2000). This method involved 
injecting the indicator, lithium chloride, into a catheter inserted into the jugular 
vein and measuring the diluted concentration of lithium in a blood sample 
obtained from a peripheral arterial site using a sensor that is selective for 
lithium. The housing for the sensor included inlet and outlet ports. The inlet port 
was attached to the catheter inserted in the transverse facial artery via a 3-way 
valve, and the outlet port attached via tubing to a disposable blood collection 
bag. The tubing between the sensor and collection bag passed through a flow 
regulator pump. When the pump was activated, arterial blood passed through 
the sensor at a constant rate (4 mL min-1). This sensor consisted of a flow 
through cell housing a lithium-selective electrode. When the lithium-selective 
membrane was in contact with blood, the voltage across it was related to 
plasma lithium concentration by the Nernst equation. This voltage was 
measured by use of an isolated amplifier, digitized on-line, and analysed with a 
LiDCO cardiac monitor. To measure cardiac output via this technique, the 
LiDCO cardiac monitor required the input of the sensor constant, the injection 
dose of lithium chloride, haemoglobin concentration and serum sodium 
concentration of each horse. When the baseline voltage recorded from the 
lithium electrode was stable, the injection dose was placed into an extension 
set attached to the jugular catheter. A subsequent volume (10 mL) of 
heparinized saline (0.9% NaCl) solution was then injected rapidly to flush in the 
lithium chloride. A dose rate of lithium chloride was adjusted to achieve an ideal 
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lithium concentration between 0.2 and 0.8 mM (1.5 mL of lithium chloride 1.5 
molar). Thus, an optimal adequacy of measurement was guaranteed. The 
information generated by the sensor and transmitted to the LiDCO monitor 
generated a concentration time curve for lithium. The obtained area under the 
curve (AUC) after the first peak represented the stroke volume (SV). Cardiac 
output (CO, L min-1) was calculated as SV x HR. The cardiac index (CI) was 
calculated by using 2 formulas: 
• CI (mL min-1 kg-1) = [CO/BW] x 1000  
where bodyweight (BW) was measured in kilograms 
• CI (L min-1 m-2) = CO/BSA  
where body surface area (BSA)  = 10.5 x body weight (g)2/3 x 10-4 (m2) 
 
Anaesthesia recovery  
Twenty minutes before the end of the surgical procedures, 0.1 mg kg-1 
morphine (Morphin HCl Sintetica, Sintetica SA, Mendrisio, Switzerland) was 
administered intramuscularly for postoperative analgesia. After surgical 
procedure, the ventilator was switched off and the patients were left to recover 
spontaneous respiration. Each horse was placed into a padded recovery box 
and oxygen was delivered through the nostrils (10 L min-1). The whole recovery 
period was video recorded for further analysis. At the first sign of swallowing 
and/or nystagmus, the endotracheal tube was removed, post anaesthetic 
sedation administered (both groups: medetomidine 2 µg kg-1, IV) and the time 
recorded. Times to achieve sternal and standing positions were recorded. After 
complete recovery from anaesthesia, the patients were transferred to their 
respective boxes in the clinic. 
By use of the video recordings, the quality of anaesthesia recovery was 
evaluated by four experienced anaesthetists (all Dipl ECVAA) of the 
Anaesthesia Section of the Equine Department of the Vetsuisse Faculty of 
Zurich, by using a modified score recovery quality system (numeric rating 
score, NRS) for horses (Table 1). 
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Table 1- Description of the numeric rating score (NRS) used for assessing the quality  
of the recovery phase (adapted from Mama et al. 1996) 
 
    Score        Description 
1 Excellent 
Quiet, coordinated efforts (1 - 2) to achieve sternal and standing 
position. No or light ataxia once standing. Calm. 
2 
 
Good 
Quiet, slightly uncoordinated efforts (1 - 2) to achieve sternal or 
standing positions. Mild ataxia once standing. Calm. 
3 
 
Fair 
Multiple (≥ 3) quiet attempts to achieve sternal and standing 
positions. Mild to considerable ataxia once standing. Calm. 
4 Moderate 
Multiple (≥ 3) uncoordinated attempts to achieve sternal and 
standing positions. Moderate excitement. 
5 
 
Poor 
Unable to stand up two hours after extubation. Horse required 
additional sedation because of severe excitement. 
 
In addition, a visual analogue scale (VAS) from 0 mm (best possible recovery) 
to 100 mm (worst possible recovery) was used.  
 
 
3.5 Statistical methods 
The NCSS 2004 software package (Kaysville, Utah, USA) was used to perform 
the statistical evaluation.  
All data was analysed for normal distribution with the Shapiro-Wilk W test. The 
significance of difference between groups for parametric data was assessed 
with Student’s t-tests and for non-parametric variables by using the Mann-
Whitney U and Kruskal-Wallis tests. Proportions were evaluated with Chi-
Square tests. For all tests p < 0.05 was considered the minimum level of 
statistical significance. 
For intra-anaesthetic continuous response variables, which included heart rate, 
respiratory rate, arterial blood pressures, end-tidal concentration of isoflurane, 
end-tidal carbon dioxide partial pressure, inspired oxygen fraction, cardiac 
output, cardiac index and arterial blood gas values (PaO2, PaCO2, SaO2, pH), 
all available measurements were included in the statistics, accepting that 
therefore animals would not be represented equally in the dataset.  
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Recovery scores (VAS and NRS) obtained from the 4 observers were averaged 
to obtain a single score for each horse. For each group, recovery quality 
parameters were associated with the length of infusions and with the times to 
achieve the sternal and standing positions by use of the Pearson correlation 
coefficient (r) and linear regression analysis, and significance was tested by use 
of the Student t test.  
Parametric data is presented as mean ± standard deviation and non-parametric 
data is presented as median, range, interquartile ranges (box plots) or by use of 
descriptive statistics.  
 
4. RESULTS 
4.1 Study animals and pre-anaesthesia examination 
 
Animal details 
A total of 50 horses were enrolled in the study. All horses were allocated to two 
groups of 25 individuals each. Most of them (70%) were warmblood horses. 
The rest of the population consisted in Quarter horses (8%), thoroughbreds 
(6%), Freibergers (4%), ponies (4%), Pure Spanish Horses (2%), Palominos 
(2%), Arabian horses (2%) and Friesian horses (2%). 
 
Demographics of horses are detailed in the tables below (Tables 2a & b). 
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Table 2a- Demographics of horses allocated to Med group (F = female, M = male, 
MC= male castrated) 
CRF Age (years) Weight (kg) Breed Sex Surgery 
1 17 725 Irish Warmblood  MC neurectomy 
3 3 455 CH Warmblood M castration 
4 2 420 Thoroughbred M castration 
8 8 555 CH Warmblood F arthroscopy 
9 2 420 CH Warmblood MC arthroscopy 
10 6 500 Quarter Horse F arthroscopy 
13 18 610 Selle Français MC sarcoid 
14 7 625 Holstein MC arthroscopy 
18 8 550 Hanoverian MC arthroscopy 
21 7 515 Freiberger F arthroscopy 
22 1 260 CH Warmblood F plate removal 
24 6 520 Hanoverian F osteophyte removal 
26 1 370 CH Warmblood M castration 
28 14 620 German Warmblood MC arthroscopy 
29 13 460 Warmblood M castration 
30 3 480 CH Warmblood M castration 
34 8 580 CH Warmblood F arthroscopy 
35 1 295 Quarter Horse M castration 
37 3 480 CH Warmblood M castration /chip 
39 9 670 CH Warmblood MC arthroscopy/ tendovaginoscopy 
44 3 350 Icelandic Pony M castration 
45 5 500 Quarter Horse M arthroscopy 
46 5 620 Freiberger F fetlock/arthroscopy 
47 15 410 Pony F wound flush 
49  660 Holstein F desmotomy 
Mean  506    
SD  118    
Median 6     
Min 1     
Max 18     
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Table 2b- Demographics of horses allocated to S-ket group (F = female, M = male, 
MC= male castrated) 
CRF Age (years) Weight (kg) Breed Sex Surgery 
2 2 520 CH Warmblood M arthroscopy/castration 
5 18 500 Russian Horse MC splint bone resection 
6 4 620 Selle Français M castration/hernia 
7 9 540 CH Warmblood M castration 
11 4 630 German Warmblood MC sequester 
12 5 440 Arabian Horse M castration 
15 11 630 Trakehner F neurectomy 
16 9 510 PRE M neurectomy 
17 10 580 Holstein MC arthroscopy 
19 6 600 Selle Français M castration 
20 3 465 Friesian M castration 
23 9 430 Quarter Horse F Tenovaginoscopy/ desmotomy 
25 10 540 CH Warmblood M castration 
27 9 380 Iceland F exostosis 
31 3 520 CH M castration 
32 13 545 CH MC arthroscopy 
33 6 500 Thoroughbred MC arthroscopy 
36 15 580 Irish Warmblood MC neurectomy 
38 8 570 CH Warmblood F joint flush 
40 13 650 Oldenburg MC arthroscopy/neurectomy 
41 11 600 Italian Warmblood F arthroscopy 
42 12 575 CH Warmblood F arthroscopy 
43 3 500 Poland Warmblood M arthroscopy/castration 
48 13 590 Oldenburg MC neurectomy 
50 5 550 Thoroughbred F arthrodesis 
Mean  542    
SD  67    
Median 9     
Min 2     
Max 18      
 
 
There were no differences between groups in regard to distribution of sex 
(Table 3) (p = 0.83), ASA grading (Table 4) (p = 0.19), age (p = 0.13; Med 
group: 6 [1 – 18] years; S-ket group: 9 [2 – 18] years) and body weight (p = 
0.18; Med group: 506 ± 118 kg; S-ket group: 542 ± 67 kg).  
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Table 3- Distribution of sex (F = female, M = male, MC= male castrated) 
Group F M MC Total 
Med group 9 (36%) 9 (36%) 7 (28%) 25 (100%) 
S-ket group 7 (28%) 10 (40%) 8 (32%) 25 (100%) 
Total 16 (32%) 19 (38%) 15 (30%) 50 (100%) 
 
 
 
 
Table 4- Distribution of ASA grading (I=normal healthy patient; II=patient with mild  
systemic disease; III=patient with severe systemic disease) 
 I II III Total 
Med group 6 (24%) 16 (64%) 3 (12%) 25 (100%) 
S-ket group 8 (32%) 17 (68%) 0 (0%) 25 (100%) 
Total 14 (28%) 33 (66%) 3 (6%) 50 (100%) 
 
 
No differences between groups in regard to distribution of surgery types were 
detected (p = 0.18; "IV": invasive orthopaedic procedures, "NIV": minimally 
invasive orthopaedic or dermatological procedures, "Neu": neurectomies and 
"Ctr": castrations) (Table 5). If two procedures were performed simultaneously, 
horses were allocated to the group considered to cause more nociceptive 
stimulation (i.e. castration and non-invasive arthroscopy allocated to "Ctr"). 
 
 
 
Table 5- Distribution of surgery types (IV=invasive orthopaedic procedures; NIV=minimally 
invasive orthopaedic or dermalogical procedures; Neu= neurectomies; Ctr= castrations) 
 IV NIV Neu Ctr Total 
Med group 4 (16%) 12 (48%) 1 (4%)   8 (32%) 25 (100%) 
S-ket group 5 (20%)   6 (24%) 5 (20%)   9 (36%) 25 (100%) 
Total 9 (18%) 18 (36%) 6 (12%) 17 (34%) 50 (100%) 
 
 
 
Baseline heart rate (HR) (p = 0.96), body temperature (T°C) (p = 0.20), 
haematocrit (Hto) (p = 0.72) and total proteins (TP) (p = 0.42) obtained before 
pre-medication were also not different between groups. There was only a trend 
for differences in respiratory frequencies RR (p = 0.06). 
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Table 6a- Pre-clinical examination performed in horses  
allocated to Med group 
CRF HR RR T Hto TP Pulse ASA 
1 28 8 38 41 62 strong II 
3 36 8 37.9 31 58 strong II 
4 36 12 37.8 35 60 good II 
8 40 16  34 57 good II 
9 32 12 38 23 62 strong II 
10 40 14 37.7 40 66 strong II 
13 34 12 37.9 29 63 strong II 
14 33 10 38 35 62 strong II 
18 32 12 37.9 36 62 strong II 
21 40 12 37.9 34 62 strong II 
22 38 10 37.8 38 60 strong II 
24 44 15 37.9 33 64 good III 
26 40 12 37.8 38 67 normal I 
28 32 12 37.9 30 60 strong II 
29 48 18 37.7 42 68 normal I 
30 40 18 37.9 36 68 strong I 
34 36 12  37 69 strong II 
35 56 16 38.6 30 52 strong I 
37 36 8 37.9 30 67 strong I 
39   38.1 40 60 strong II 
44 38 12 37.9   strong I 
45    26 52  III 
46 32 14 38 28 68 strong II 
47 32 8 37.5 25 70 strong III 
49 32 12  28 58 strong II 
Mean    33.3 62.4   
SD    5.3 4.9   
Median 36 12 37.9     
Min 28 8 37.5     
Max 56 18 38.6     
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Table 6b- Pre-clinical examination performed in horses  
allocated to S-ket group 
CRF HR RR T Hto TP Pulse ASA 
2 36 10 37.9 29 67 normal II 
5 36 12 38 26 52 strong II 
6 36 16 37.8 31 62 normal I 
7 32 16 37.8 43 61 strong I 
11 30 8 37.9 39 64 strong II 
12 36 16 37.7 40 60 normal I 
15 36 12 37.8 29 64 strong II 
16 40 12 37.8 33 64 strong II 
17 32 8 37.4 43 70 strong II 
19 36 8 37.7 38 58 strong I 
20 36 12  35 58 strong I 
23 46 12 37.7 36 65 strong II 
25 36 8 37.7 38 58 strong I 
27 38 8 37.8 33 60 strong II 
31 44 16  36 70 strong I 
32 40 8  31 63 strong II 
33 32 8 38 34 59 strong I 
36 44 10 38.1 36 58 strong II 
38 36 10 38.2 27 64 strong II 
40  32 10 37.9 31 64 strong II 
41 36 8 38 33 56 strong II 
42 32 10 37.9 34 60 strong II 
43 32  38 33 66 normal II 
48 36 8 37.2 27 58 strong II 
50 48 16  30 50 strong II 
Mean    33.8 61.2   
SD    4.7 4.8   
Median 36 10 37.8     
Min 30 8 37.2     
Max 48 16 38.2     
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4.2 Anaesthesia 
No serious adverse event occurred during the whole anaesthetic episode. 
Median CRI times were not significantly different between groups (Med 
group: 117 [70 - 231] minutes; S-ket group: 115 [77 – 239] minutes) (p = 
0.90).  
The distribution of horses in lateral or dorsal recumbency was not different  
(p = 0.57) between groups (Table 7). 
 
Table 7- Distribution of recumbency during anaesthesia. 
Group dorsal  recumbency  
lateral  
recumbency Total 
Med group 13 (52%)   12 (48%) 25 (100%) 
S-ket group 15 (60%)   10 (40%) 25 (100%) 
Total 28 (56%)   22 (44%) 50 (100%) 
 
In both groups, the same proportions of horses had an Esmarch's bandage 
for surgical haemostasis (p = 0.75). 
Median intra-anaesthetic end-tidal concentrations of isoflurane (FE'iso) 
required to maintain an adequate plane of anaesthesia were similar between 
groups (both groups: 1% (p = 0.91) (Figure 11).  
 
Figure 11- Intra-anaesthetic end-tidal concentrations of isoflurane (FE'iso) 
required to maintain an adequate plane of anaesthesia obtained in horses 
anaesthetised with isoflurane and a CRI of medetomidine (Med; n = 25) or 
S(+)-ketamine (S-ket; n = 25). Boxes represent the 25th interquartile range, 
bars the 75th interquartile range, the horizontal line the median and  the 
outliers. No significant differences between groups (p = 0.91). 
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However, horses in S-ket group required significantly higher (p = 0.03) 
thiopental doses to maintain an adequate anaesthetic depth than horses in 
Med group (Med group: 0 [0 – 0.38] mg kg-1; S-ket group: 0.1 [0 – 0.61] mg 
kg-1).  
 
Haemodynamic and respiratory data 
Overall, median intra-anaesthetic heart rates (HR) were not significantly 
different between both groups (Med group: 32 [23 - 51] beats min-1; S-ket 
group: 32 [24 - 89] beats min-1) (p = 0.07) (Figure 12). However, during the 
first 15 minutes of anaesthesia, heart rates were significantly higher in Med 
group than in S-ket group, whereas 60, 70, 75, 80 and 90 minutes after 
begin of anaesthesia, horses in S-ket group experienced significantly higher 
heart rate values than horses in Med group. Evaluation of the individual plots 
showed that in total 7 horses experienced individual heart rates above 50 
beats min-1 (Med: n = 1; S-ket: n = 6).  
 
 
Figure 12- Intra-anaesthetic heart rates (HR) over time 
obtained from horses anaesthetised with isoflurane 
and a constant rate infusion of medetomidine (Med 
group) or S(+)-ketamine (S-ket group) (n decreasing 
with time) (p = 0.07). 
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The median dose of dobutamine necessary to maintain the target mean 
arterial blood pressure (MAP) of 70 – 100 mmHg (Med-group: 0.015 [0.001 – 
0.055] mg kg-1 hour-1; S-ket group: 0.018 [0.004 – 0.066] mg kg-1 hour-1, 
during the whole anaesthetic episode was not different between groups (p = 
0.31) (Figure 13). 
 
Figure 13- Intra-anaesthetic dobutamine dose necessary to 
maintain a target MAP of 70-100 mmHg obtained from horses 
anaesthetised with isoflurane and a constant rate infusion of 
medetomidine (Med; n = 25) or S(+)-ketamine (S-ket; n = 25). Boxes 
represent the 25th interquartile range, bars the 75th interquartile 
range, the horizontal line the median. No significant differences 
between groups (p = 0.31). 
 
Mean arterial blood pressure (MAP) (Med group: 83 [42 - 139] mmHg; S-ket 
group: 83 [51 - 133] mmHg) and diastolic arterial blood pressure (DAP) (Med 
group: 70 [36 - 137] mmHg; S-ket group: 69 [41 – 121] mmHg) were not 
different in both groups (p = 0.13 and 0.12, respectively) (Figures 14 & 15). 
Systolic arterial blood pressure was significantly higher in Med group (110 
[59 - 162] mmHg) than in S-ket group (106 [60 - 156] mmHg) (p = 0.02) 
(Figure 16). 
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Figure 14- Mean arterial blood pressure (MAP) over time 
measured in horses anaesthetised with isoflurane and a CRI of 
medetomidine (Med group) or S(+)-ketamine (S-ket group) (n 
decreasing with time) (p = 0.13). 
 
 
Figure 15- Diastolic arterial blood pressure (DAP) over time 
measured in horses anaesthetised with isoflurane and a CRI of 
medetomidine (Med group) or S(+)-ketamine (S-ket group) (n 
decreasing with time) (p = 0.12). 
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Figure 16- Systolic arterial blood pressure (SAP) over time 
measured in horses anaesthetised with isoflurane and a CRI of 
medetomidine (Med group) or S(+)-ketamine (S-ket group) (n 
decreasing with time) (p = 0.02). 
 
 
Values obtained for cardiac output (CO) in Med group ranged between 12.38 
and 79 L min-1, and in S-ket group between 16.31 and 59.84 L min-1.  
The median cardiac index (CI = cardiac output indexed to body surface)  
(L min-1 m-2) was significantly higher (p < 0.01) in S-ket group (4.47 [2.6 – 8.5] L 
min-1 m-2) compared with Med group (3.93 [2.3 – 9.9] L min-1 m-2) (Figure 17).  
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Figure 17- Cardiac Index (L min-1 m-2) obtained from horses 
anaesthetised with isoflurane and a CRI of medetomidine (Med) or 
S(+)-ketamine (S-ket). Boxes represent the 25th interquartile range, 
bars the 75th interquartile range, the horizontal line the median and  
the outliers. *Cardiac Index was significantly higher in S-ket group (p < 
0.01) 
 
 
Similarly, the median CI (mL min-1 kg-1) in which the weight of the patient, but 
not the BSA is taken into account, was significantly higher in S-ket group (59 
[32 – 109] mL min-1 kg-1) than in Med group (52 [31 – 123] mL min-1 kg-1) (p  
< 0.01) (Figure 18). 
 
51 
 
 
Figure 18- Cardiac Index (mL min-1 kg-1) obtained from horses 
anaesthetised with isoflurane and a CRI of medetomidine (Med) or S(+)-
ketamine (S-ket). Boxes represent the 25th interquartile range, bars the 
75th interquartile range, the horizontal line the median and  the outliers. 
*Cardiac Index was significantly higher in S-ket group (p < 0.01). 
 
 
Overall, horses in both groups showed a similar degree of respiratory 
acidosis evidenced by PaCO2 values above 45 mmHg. In 3 horses, 2 
allocated to Med group and 1 allocated to S-ket group, that were all 
positioned in dorsal recumbency, PaO2 was below 70 mmHg at 15 minutes 
after anaesthesia induction (54.9, 66.2 and 64 mmHg, respectively) and 
required salbutamol administration. The PaO2 values at 30 minutes after 
anaesthesia induction were 124, 188 and 103 mmHg, respectively and no 
further salbutamol had to be given. Overall, PaO2 values were significantly 
lower for horses in S-ket group than in Med group (p < 0.01). The ratio of the 
partial pressure of oxygen in arterial blood to the inspired oxygen fraction 
(PaO2/Fi'O2) showed in both groups mean values above 200 mmHg at every 
time point but only horses allocated to Med group showed mean PaO2/Fi'O2 
values above 300 mmHg at every sampling time. This difference was found 
to be statistically significant (p < 0.01). Still, both groups had PaO2 values 
above 100 mmHg at all times. Although the statistical test detected 
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significant differences for pH values, on average, both groups had values 
within the expected normal range (7.24 – 7.46). 
 
Results of arterial blood gases obtained 15, 30, 60, 90, 120, 150, 180, 210 
and 240 after anesthesia induction are detailed below (Table 8). 
 
 
Table 8- Mean ± SD values for arterial blood gases obtained at 15, 30, 60, 90, 120, 
150, 180, 210 and 240 minutes after anaesthesia induction in horses anaesthetised 
with isoflurane and receiving a constant rate infusion of medetomidine (Med group) or 
S(+)-ketamine (S-ket group). 
Time 
(min) 
Group n  pH PaCO2  
(mmHg) 
PaO2 
(mmHg) 
SaO2  
(%) 
PaO2/Fi'O2 
(mmHg) 
 
15 
 
 
Med 25 7.35±0.04 50.7±7.1 197±107 
 
98.8±2.4 
 
333±141 
 
S-ket 25 7.38±0.04 49±5.5 143±74 98.6±2.2 261±126 
 
30 
 
Med 24 7.35±0.04 52.3±5.9 223±87 
 
99.7±0.5 359±139 
 
S-ket 25 7.37±0.04 
 
51.4±5.6 186±86 
 
99.4±1.1 309±149 
 
 
60 
 
Med 25 7.35±0.04 54.6±5.9 254±93 
 
99.8±0.4 378±127 
 
S-ket 25 7.36±0.04 53.3±4.5 191±68 
 
99.6±1.2 302±118 
 
 
90 
 
Med 22 7.35±0.04 56.4±6.2 243±100 
 
99.7±0.6 365±133 
 
S-ket 23 7.36±0.03 54.5±6.3 194±81 99.6±0.6 296±129 
 
 
120 
 
Med 11 7.35±0.03 56.6±5.6 248±110 99.3±1.4 366±172 
 
S-ket 13 7.36±0.03 55.6±7.9 221±115 99.3±1.5 330±178 
 
 
150 
 
Med 7 7.35±0.04 55.1±3.7 264±98 
 
99.6±0.7 400±144 
 
S-ket 8 7.36±0.03 58.3±9.8 199±94 99.4±1.3 313±155 
 
 
180 
 
Med 3 7.33±0.05 58.4±8.3 243±115 
 
99.9±0 379±213 
 
S-ket 4 7.37±0.04 58.1±8.0 228±92 99.8±0.4 360±157 
 
 
210 
 
Med 2 7.29±0.06 69.2±9.1 196±126 
 
99.7±0.2 302±256 
 
S-ket 0      
 
240 
 
Med 1 7.27 73 181 99.5 152 
 
S-ket 0      
 
All 
Med 120 7.35±0.04 54.4±6.9 232±98 99.5±1.3 359±140 
 
S-ket 123 7.37±0.04 52.9±6.6 186±85 99.5±2.5 300±137 
 
 
 
 
 
 
 
 
 
p 
  
< 0.01 
 
0.11 
 
< 0.01 
 
0.98 
 
< 0.01 
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Median inspired oxygen fraction (Fi'O2) values were not significantly different 
between groups (Med group: 65 [40 - 94]%; S-ket group: 63 [38 - 97]%) (p = 
0.14) (Figure 19).  
 
 
Figure 19- Inspired oxygen fraction (Fi'O2) obtained from horses 
anaesthetised with isoflurane and a CRI of medetomidine (Med group; 
n = 25) or S(+)-ketamine (S-ket group; n = 25). Boxes represent the 
25th interquartile range, bars the 75th interquartile range, the horizontal 
line the median and  the outliers. No significant differences between 
groups (p = 0.14).  
 
     
In Med group, median values for PaO2/Fi'O2 were not different for patients in 
dorsal recumbency (356 [59 - 664] mmHg) compared with lateral 
recumbency (365 [149 - 570] mmHg (p = 0.26). In S-ket group, median 
values of PaO2/Fi’O2 were lower for patients in dorsal recumbency (185 [88 - 
537] mmHg) when compared with lateral recumbency (413 [148 - 591] 
mmHg) (p < 0.01). Median values of PaO2/Fi'O2 were not significantly 
different between groups for patients in lateral recumbency (p = 0.95), but 
were significantly lower for patients in dorsal recumbency allocated to S-ket 
group (p < 0.01) (Figure 20). 
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Figure 20- PaO2/Fi'O2 (mmHg) obtained from horses anaesthetised with isoflurane 
and a CRI of medetomidine (Med group) or S(+)-ketamine (S-ket group). Boxes 
represent the 25th interquartile range, bars the 75th interquartile range, the 
horizontal line the median. *In horses anaesthetised in dorsal recumbency 
PaO2/Fi'O2 was significantly higher in Med group (p < 0.01). In S-ket group horses 
in dorsal recumbency had significantly lower PaO2/Fi'O2 than horses in lateral 
recumbency (p < 0.01).    
 
Throughout anaesthesia, median respiratory rate (RR) values were similar 
between groups (Med group: 7 [2 - 20] breaths min-1; S-ket group: 7 [3 - 17] 
breaths min-1) (p = 0.32). However, median values obtained for end-tidal 
carbon dioxide partial pressure (PE'CO2) (Med group: 48 [34 - 64] mmHg; S-
ket group: 45 [30 - 64] mmHg) were significantly different between groups (p 
< 0.01). 
 
4.3 Anaesthesia recovery 
Horses allocated to S-ket group regained sternal recumbency significantly 
faster (38 [8 - 75] minutes) compared with those allocated to Med group (48 
[10 - 72] minutes) (p = 0.01) (Figure 21). Subsequently, horses allocated to 
S-ket group stood up significantly faster (50 [18 - 91] minutes) than those 
allocated to Med group (60 [20 - 99] minutes) (p = 0.02) (Figure 22). 
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Figure 21- Time to achieve sternal position in horses after anaesthesia with 
isoflurane and a CRI of medetomidine (Med group; n = 25) or S(+)-
ketamine (S-ket; n = 25). Boxes represent the 25th interquartile range, bars 
the 75th interquartile range, the horizontal line the median.  *Horses in S-ket 
group regained significantly faster sternal position (p = 0.01). 
 
 
Figure 22- Time to achieve standing position in horses after anaesthesia 
with isoflurane and a CRI of medetomidine (Med group; n = 25) or S(+)-
ketamine (S-ket group; n = 25). Boxes represent the 25th interquartile 
range, bars the 75th interquartile range, the horizontal line the median.  
*Horses in S-ket group regained significantly faster standing position (p = 
0.02). 
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Median recovery visual analogue scale (VAS) values were statistically 
significantly lower for horses in Med group (14.5 [4 - 89] mm) when 
compared with horses in S-ket group (31.75 [1.5 – 93.25] mm) (p = 0.01) 
(Figure 23).  
 
 
Figure 23- Visual analogue scale (VAS; 0 mm = best possible 
recovery; 100 = worst possible recovery) obtained from the evaluation 
of the anaesthesia recovery quality by 4 observers. Horses were 
anaesthetised with isoflurane and a CRI of medetomidine (Med group; 
n = 25) or S(+)-ketamine (S-ket group; n = 25). Boxes represent the 
25th interquartile range, bars the 75th interquartile range, the horizontal 
line the median and  the outliers. *VAS was significantly better in 
Med group (p = 0.01). 
 
 
Median recovery numeric rating score (NRS) (1 = excellent, 2 = good, 3 = 
fair, 4 = moderate, 5 = poor) was also significantly lower for patients in Med 
group (1.25 [1 - 5]) than for patients in S-ket group (2.25 [1 - 5]) (p < 0.01) 
(Figure 24). One horse in each group was scored as "poor" (NRS=5). The 
horse allocated to Med group required additional sedation.  
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Figure 24- Numeric rating score (1 - 5; 1 = excellent; 5 = poor) obtained from the 
evaluation of the anaesthesia recovery quality by 4 observers. Horses were anaesthetised 
with isoflurane and a CRI of medetomidine (Med group; n = 25) or S(+)-ketamine (S-ket 
group; n = 25). Boxes represent the 25th interquartile range, bars the 75th interquartile 
range, the horizontal line the median and  the outliers. *NRS score was significantly 
better in Med group (p < 0.01). 
 
 
There was a correlation between the duration of the infusion and the quality 
of anaesthesia recovery for horses in S-ket group (p = 0.02), but not for 
horses in Med group (p = 0.52) (Figure 25). 
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Figure 25- Visual analogue scale values (VAS) obtained from the evaluation of anaesthesia 
recovery quality by 4 observers. Horses were anaesthetised with isoflurane and a CRI of 
medetomidine (a. Med group; n = 25 horses) or S(+)-ketamine (b. S-ket group; n = 25 horses) 
Data for VAS were plotted over duration of CRI and linear correlation (straight line) and 
Pearson correlation coefficient (r) were calculated. Only VAS values of horses allocated to S-
ket group had a strong correlation with the length of the CRI.  
 
 
 
When plotted over time to regain sternal and standing position, horses 
allocated to both groups showed a significant negative correlation with 
anaesthesia recovery VAS (Figures 26 & 27). The faster horses regained 
sternal and standing position the poorer recovery quality was (Med group: p 
< 0.01; S-ket group: p = 0.01 respectively p = 0.04). 
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Figure 26- Visual analogue scale values (VAS) obtained from the evaluation of the 
anaesthetic recovery quality by 4 observers. Horses were anaesthetised with isoflurane and 
a CRI of medetomidine (a. Med group: n = 25) or S(+)-ketamine (b. S-ket group; n = 25). 
Data for VAS were plotted over time to regain sternal position and linear correlation (straight 
line) and Pearson correlation coefficient (r) were calculated. VAS values of horses allocated 
to both groups had a negative correlation with time to sternal position. 
 
 
 
 
 
Figure 27- Visual analogue scale values (VAS) obtained from the evaluation of the 
anaesthesia recovery quality by 4 observers. Horses were anaesthetised with isoflurane and 
a CRI of medetomidine (a. Med group; n = 25) or S(+)-ketamine (b. S-ket group; n = 25). 
Data for VAS were plotted over time to regain standing position and linear correlation 
(straight line) and Pearson correlation coefficient (r) were calculated. VAS values of horses 
allocated to both groups had a negative correlation with time to standing position. 
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There were no correlations between the amount of thiopental administered 
and the mean VAS values (Med group: p = 0.40; S-ket group: p = 0.48) 
(Figure 28). 
 
 
Figure 28- Visual analogue scale values (VAS) obtained from the evaluation of the 
anaesthesia recovery quality by 4 observers. Horses were anaesthetised with isoflurane and 
a CRI of medetomidine (a. Med group; n = 25) or S(+)-ketamine (b. S-ket group; n = 25). 
Data for VAS were plotted over thiopental dose necessary to maintain an adequate 
anaesthetic depth. Linear correlation (straight line) and Pearson correlation coefficient (r) 
were calculated. No correlation could be detected. 
 
 
5. DISCUSSION 
The aim of the present study was to compare the effects on MAC and 
cardiopulmonary function of a constant rate infusion of S(+)-ketamine with a 
constant rate infusion of medetomidine during isoflurane anaesthesia in 
horses and the resulting recovery duration and quality. Fifty horses 
undergoing elective surgical procedures in every part of the body except the 
neck and the head regions were randomly allocated to receive S(+)-ketamine 
CRI or medetomidine CRI during isoflurane anaesthesia. The identity of the 
treatment was blinded for the anaesthetist. There was no difference 
concerning the effects on MAC, but cardiac index was slightly better with 
S(+)-ketamine. On the other hand, recovery quality was better following 
medetomidine. 
Eight to sixteen hours before anaesthesia, food was withheld to avoid the  
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hazards of food aspiration after anaesthesia induction and to reduce the 
effects of intra-operative tympanism that may interfere with free movement of 
diaphragm and perturb breathing. 
Anaesthesia was induced with either 2.2 mg kg-1 racemic ketamine (Med 
group) or 1.1 mg kg-1 S(+)-ketamine (S-ket group). In a previous study 
performed in horses sedated with xylazine, 2/3 of the racemic dose was 
given for S(+)-ketamine (Filzek et al. 2003). In the present study, only half of 
the racemic dose was administered, as S(+)-ketamine has approximately 
twice the anaesthetic potency of racemic ketamine (Ryder et al. 1978, White 
et al. 1980, Kohrs & Durieux 1998). Preliminary studies in our clinic have 
shown that this is also the case in horses (unpublished data). 
Horses in both treatment groups required similar concentrations of isoflurane 
to maintain anaesthesia. However, horses receiving S(+)-ketamine CRI 
required significantly higher doses of thiopental as a rescue medication to 
achieve an adequate surgical anaesthetic depth than horses receiving 
medetomidine CRI. This indicates that horses allocated to Med group had a 
more stable anaesthesia than horses allocated to S-ket group. The strong 
sedative effects of medetomidine might have resulted in a more profound 
hypnosis in comparison to S(+)-ketamine which resulted in a reduced need 
for incremental thiopental in this group. Overall, median intra-anaesthetic 
heart rates (HR) were not different between both groups. However, during 
the first 15 minutes of anaesthesia, horses in Med group showed significantly 
higher heart rates than horses in S-ket group. The loading dose of racemic 
ketamine in Med group may be responsible for this result. In a study 
comparing the effects of repetitive boli of racemic and S(+)-ketamine, mean 
heart rate was also significantly higher with racemic ketamine (Filzek et al. 
2003). Twenty minutes after the beginning of anaesthesia, heart rate slightly 
decreased in horses allocated to Med group. Sixty, 70, 75, 80 and 90 
minutes after the beginning of anaesthesia, horses in S-ket group showed 
significantly higher values than horses in Med group. Evaluation of the 
individual plots showed that in total 7 horses experienced individual heart 
rates above 50 beats min-1 (Med: n = 1; S-ket: n = 6). These high heart rate 
values mainly occurred during surgery, suggesting intraoperative 
sympathomimetic stimulation. This stimulation might either be induced by 
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S(+)-ketamine directly (White et al. 1982, Adams & Werner 1997, Zielmann 
et al. 1997) or be a result of surgical stimulation. Especially in one horse 
undergoing surgical castration and allocated to S-ket group, intra-anaesthetic 
heart rates increased over 80 beats min-1 at time points 80 and 90, 
immediately after requiring a rescue dose of thiopental to maintain an 
adequate surgical anaesthetic plane. It remains unclear whether this 
increase was the consequence of direct sympathomimetic stimulation of 
S(+)-ketamine, of intraoperative nociception or of both. On the other hand, 
medetomidine decreases heart rate and blunt responses to surgical 
stimulation to a certain extent (Ringer et al. 2007), which certainly helped to 
reduce the incidence of tachycardia in this group. 
The cardiac index (CI), the main indicator of muscular perfusion in horses 
(Lee et al. 1998), was significantly higher in S-ket group than in Med group. 
Therefore muscular perfusion was better with S(+)-ketamine. The CI values 
observed in Med group were similar to those reported in a previous study in 
which a similar anaesthetic regime was used (Ringer et al. 2007). The CI 
values for horses in S-ket group were comparable with those reported in 
mechanically ventilated horses anaesthetised with isoflurane alone after 
sedation with romifidine and induction of anaesthesia with a combination of 
ketamine and diazepam (Blissitt et al. 2008). 
Alpha2-adrenoceptor agonists usually induce an initial increase in arterial 
blood pressure followed by a longer lasting decrease. In this study, a 
dobutamine infusion was given to all horses and the dosages were adjusted 
to keep a target mean arterial blood pressure between 70 and 100 mmHg. 
Horses in both groups required the same dose of dobutamine to maintain 
this target MAP. Mean arterial blood pressure was not statistically different 
throughout the whole anaesthetic episode. 
 
In anaesthetised horses, hypoxemia, hypercapnia and acid-base 
disturbances often occur as a result of impaired pulmonary gas exchange 
such as hypoventilation, ventilation-perfusion mismatch and right-to-left 
vascular shunts (Schatzmann 1995, Kalchofner et al. 2009). Lung 
atelectasis, leading to poor oxygenation of the non-oxygenated blood arriving 
to the lungs, often occurs (Schatzmann 1995). In the present study, overall 
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arterial PaCO2 levels were in the same range in both groups. This reflected 
the pattern of mechanical ventilation which aimed at keeping the end-tidal 
carbon dioxide pressure between 45 and 55 mmHg. PaO2 values were 
statistically significantly lower in S-ket group than in Med group whilst median 
Fi'O2 values were not different between both groups. However, mean PaO2 
values were above 100 mmHg in both groups and as the mean SaO2 values 
remained above 99%, the difference is not considered clinically relevant.  
The degree of impairment of pulmonary gas exchange can be assessed by 
the ratio of the partial pressure of oxygen in arterial blood (PaO2) to the 
inspired oxygen fraction (PaO2/Fi'O2) (Rice et al. 2007). In humans, values 
below 300 mmHg are associated with acute lung injury, and values below 
200 mmHg are associated with acute respiratory distress syndrome (Bernard 
et al. 1994). On average, horses in the S-ket group had significantly lower 
PaO2/Fi'O2 values than horses in the Med group. In the Med group, all mean 
values were above 300 mmHg at any measured time point. Horses in S-ket 
group showed mean values below 300 mmHg, namely 261 ± 126 mmHg 15 
minutes after the beginning of anaesthesia and 296 ± 129 mmHg 90 minutes 
after the beginning of anaesthesia. These values indicate that venous 
admixture was not severe. In S-ket group, horses placed in dorsal 
recumbency had significantly lower PaO2/Fi'O2 values than horses placed in 
lateral recumbency. This finding is not surprising, as PaO2 partially depends 
on the position during recumbency (Hall et al. 1968). Nyman and 
Hedernstierna (1989) showed that horses in dorsal recumbency had a 
greater shunt than horses in lateral recumbency. Surprisingly, this issue was 
not demonstrated in Med group, even if the lowest value of 59 mmHg was 
found in this group. This value may be explained by the dorsal recumbency 
of a heavy horse (725 kg). However, the PaO2/Fi'O2 values for patients in 
dorsal recumbency were significantly lower in the S-ket group than in the 
Med group, whereas values for patients in lateral recumbency were similar 
between both groups. It seems that venous admixture was enhanced in 
horses given S(+)-ketamine only when placed in dorsal position. The 
difference in PaO2/Fi'O2 values cannot be explained by any known 
pharmacodynamic property of medetomidine or ketamine. It might be 
attributed to slightly insufficient artificial ventilation in individual horses. In 
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both groups, values for respiratory frequency lied within the reference range 
of mechanically ventilated horses. Nevertheless values for pH were 
statistically different in both groups, but were within the normal values 
expected in anaesthetised horses (Schatzmann 1995). This is more likely 
attributable to a slight difference in artificial ventilation than to a difference 
caused by the different drugs. 
 
Recovery is a very critical phase of equine anaesthesia and is often 
associated with fractures, articular dislocations, trauma and dehiscence of 
surgical wounds (Clark-Price et al. 2008). Therefore, the quality of 
anaesthesia recovery is very important, and it is a great concern in equine 
anaesthesia to achieve a quiet and coordinate recovery phase. 
Acepromazine was administered prior to anaesthesia induction. This drug 
has a long duration of action (Auckburally & Flaherty 2009) and may still 
exert sedative effects in the recovery phase, and might therefore help to 
smooth the process. It depresses the central nervous system, and therefore 
the need for other anaesthetic drugs can be reduced. Finally it has 
vasodilative effects improving muscle perfusion, and should therefore help to 
reduce the risk of development of post-anaesthetic myopathy (Auckburally & 
Flaherty 2009). As additional sedation in the early postoperative period 
improves recovery (Santos et al. 2003), medetomidine was administered to 
all horses after extubation.  
Balanced anaesthesia with isoflurane and a CRI of medetomidine leads to 
good recovery quality in ponies and horses (Kalchofner et al. 2006, 
Bettschart-Wolfensberger & Larenza 2007). It has been compared to other 
common balanced anaesthesia regimes like for example isoflurane-lidocaine, 
and was found to lead to better and smoother recovery phases (Ringer et al. 
2007). Racemic ketamine CRI's were associated with poor recovery quality 
and an increased risk of self-injuries (Spadavecchia et al. 2002, Larenza et 
al. 2009), but the use of S(+)-ketamine showed significantly better recoveries 
(Larenza et al. 2009).  
In the present study, recovery time was compared between both groups. 
Horses in S-ket group regained sternal position faster than horses allocated 
to Med group. Furthermore, horses in S-ket group stood up faster than 
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horses in Med group. Recovery quality was evaluated by four qualified 
anaesthetists, unaware of both the treatment identity and the appreciation of 
the other observers. VAS values were lower (and thus of better quality) in 
patients receiving a CRI of medetomidine than in those receiving S(+)-
ketamine. The visual analogue scale (VAS) is a model used to measure a 
characteristic or attitude that ranges across a continuum of values and 
cannot be measured directly. VAS is very subjective, and therefore some 
caution is required when handling such data, and score rankings are 
preferred by many researchers (Gould et al. 2001). NRS values of 1, 2 and 3 
are commonly considered as recoveries of adequate quality, whereas scores 
of 4 and 5 stand for inadequate recoveries. In one horse of each group, 
anaesthesia recovery was considered as poor (NRS 5). The horse allocated 
to Med group even required additional sedation to allow for a safe recovery. 
This particular horse was already very nervous at the clinical pre-
anaesthesia examination. The thoroughbred with poor recovery in S-ket 
group (CRF 50) was admitted for an arthrodesis and anaesthesia lasted for 
up to 4 hours. The temperament of the horse, the very long duration of 
anaesthesia, postoperative pain or a combination of these factors may 
explain this bad recovery. Withehair et al. (1993) demonstrated that the 
temperament of the individual horse influences recovery significantly. In 7 
horses, 2 in Med group and 5 in S-ket group, the observers were at odds 
with each other concerning recovery quality. Whilst some anaesthetists 
considered the recovery phase as good to moderate (NRS 2 to 3), and thus 
as adequate, the other observers estimated the nature of recovery as 
inadequate by allocating a NRS score of 4. Therefore, the results for 
recovery quality in the individual horses may be judged with caution. 
However, when comparing all scores between groups, horses allocated to 
Med group showed significantly lower NRS scores than horses in S(+)-ket 
group.  
Duration of anaesthesia is negatively associated to the quality of recovery 
(Young & Taylor 1993). This was confirmed in S-ket group, but not in Med 
group. In a previous study, this correlation was demonstrated in horses 
receiving racemic ketamine, but not in patients receiving S(+)-ketamine 
(Larenza et al. 2009). Because of the small number of animals involved and 
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the relatively short durations of anaesthesia in this prior study, these results 
may be judged with caution.   
Horses are flight animals and therefore tend to stand up straight after 
anaesthesia. If horses try to stand up while the remaining isoflurane is not 
completely eliminated from some body tissues, ataxia and incoordination 
may develop, increasing the risk of self-injuries. Thus, a longer recovery 
phase is associated with an improved quality of recovery (Whitehair et al. 
1993, Santos et al. 2003). In the present study, horses that took longer to 
stand up also showed better recovery quality on average. This is in contrast 
to the findings of Larenza et al. (2009), where horses receiving S(+)-
ketamine recovered faster than horses receiving racemic ketamine, but 
quality of recovery was also significantly better in the S(+)-ket group. In this 
study, the psychomimetic effects following racemic ketamine dominated 
recovery characteristics, despite the longer recoveries with this drug. 
 
In the present study, S(+)-ketamine CRI and medetomidine CRI during 
isoflurane anaesthesia provided acceptable cardiopulmonary function during 
anaesthesia in horses. Cardiac index was higher in S-ket group, but minimal 
(and thus dangerous) values recorded were not different between the 
groups. Both groups required the same concentrations of isoflurane to 
maintain anaesthesia, but more thiopental to deepen anaesthesia had to be 
used with S(+)-ketamine. Horses recovered faster with S(+)-ketamine, but 
the quality of recovery was better with medetomidine. In S-ket group, the 
longer the duration of infusion, the worse anaesthesia recovery was. 
Therefore, when using a S(+)-ketamine CRI in patients undergoing long 
lasting anaesthesia, special care must be taken to prevent the occurrence of 
injuries during recovery. 
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